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study provides a general overview of 
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time and with ageing. The role of 
demographics, diseases and other 
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factors associated with polypharmacy 
was also evaluated. It was shown 
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polypharmacy are very prevalent in 
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findings support the idea of regular 
assessments of medication as an 
integral part of comprehensive care 
for the elderly.
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ABSTRACT 
 
Increasing use of drugs in elderly persons has raised concerns about undesirable health outcomes 
associated with polypharmacy. It is widely known that polypharmacy increases the risk for adverse 
drug events that makes finding the right balance between benefits and harms of drugs difficult. The 
literature review shows an increase of polypharmacy during the last four decades, but the process 
leading to polypharmacy is largely unknown. Several sociodemographic factors have been actively 
studied as correlates of polypharmacy, while research on polypharmacy associations with indicators of 
weakened health status has been limited.  
 The overall aim of this thesis was to evaluate the changes that have occurred in drug use and 
polypharmacy over time and with ageing since the late 1990s in Finnish elderly persons. In addition, the 
study aimed at evaluating the role of demographics, diseases and health-related determinants as factors 
associated with polypharmacy. The data used are from two separate population-based cohort studies, 
the Kuopio 75+ Study (conducted in 1998 and 2003) and the GeMS Study (conducted yearly between 
2004 and 2007).  Both of these included a random population sample (n=700/Kuopio 75+, n=1000/GeMS) 
of persons 75 years and older living in the city of Kuopio.  
 Cardiovascular drugs were the most commonly used drugs. Over time and with ageing, the use of 
antithrombotic agents, vitamins and mineral supplements became more prevalent. From 1998 to 2004 the 
total mean number of drugs in use was seven. Changes were observed in the composition of medication, 
as the mean of regularly taken drugs, vitamins and mineral supplements increased, while the mean of as 
needed taken drugs decreased. Those in institutional care used about three drugs more than those living 
at home. Excessive polypharmacy (EPP, 10+ drugs) was found in every fourth and polypharmacy (PP,  
6–9 drugs) in every third elderly person. Over time, no remarkable changes occurred in the distribution 
of polypharmacy status, but with ageing the proportion of those with excessive polypharmacy increased.  
 Novel findings of this study are that the factors associated with the PP and EPP are not uniform. 
Female sex and advanced age correlated with EPP, but not with PP. Poor self-reported health was 
strongly associated with both PP and EPP. This study also indicated a high number of drugs in use per 
diagnosed disease. Of specific diseases, the association of asthma/COPD, presence of heart disease, 
diabetes, depression and pain with PP and EPP was shown. EPP was found to associate with declined 
nutritional status, functional ability and cognitive capacity, but changes over time in these three 
outcomes cannot be predicted by polypharmacy status. Overall worsening health of an individual was 
observed as an accumulation of excessive polypharmacy, nutritional deficiencies, functional inability 
and cognitive impairments. The results also showed that excessive polypharmacy, but not 
polypharmacy, can be seen as an indicator of mortality in elderly persons. 
 In conclusion, this study showed that polypharmacy and excessive polypharmacy are very prevalent 
in elderly persons, especially among the most vulnerable. These findings support the idea of regular 
assessments of medication among the elderly as an integral part of comprehensive care conducted in 
multiprofessional teams.  
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TIIVISTELMÄ 
 
Lääkkeiden käytön ja monilääkityksen yleistyminen iäkkäillä aiheuttaa huolta lääkehoidon 
mahdollisista haitoista. Monilääkityksen tiedetään lisäävän merkittävästi lääkkeiden haitta- ja 
yhteisvaikutusten riskiä. Lääkitysten hyötyjen ja haittojen arviointi tekee iäkkäiden optimaalisen 
lääkehoidon toteutuksesta haasteellista. Kirjallisuuskatsaus osoitti monilääkityksen yleistyneen 
huomattavasti viimeisen neljän vuosikymmenen aikana. Monilääkitykseen johtavia tekijöitä on 
kuitenkin puutteellisesti selvitetty. Useissa tutkimuksissa on keskitytty sosiodemografisten tekijöiden ja 
monilääkityksen välisen yhteyden selvittämiseen, kun taas terveydentilaa kuvaavien tekijöiden ja 
monilääkityksen yhteyttä on tutkittu vähän.    
 Tämän väitöskirjatyön tavoitteen oli selvittää lääkkeiden käytössä ja monilääkityksessä tapahtuneita 
muutoksia 1990-luvun lopulta lähtien suomalaisilla iäkkäillä. Lisäksi tutkimuksessa selvitettiin 
demografisten tekijöiden, sairauksien ja muiden terveydentilaa kuvaavien tekijöiden yhteyttä 
monilääkitykseen. Tutkimuksessa käytettiin kahta erillistä väestöpohjaista seuranta-aineistoa: Kuopio 
75+ (toteutettu 1998 ja 2003) ja HHS (Hyvän Hoidon Strategia, toteutettu vuosittain aikavälillä 2004–
2007) tutkimuksia. Molempien tutkimusten osallistujat valittiin satunnaisotannalla (n=700/Kuopio 75+ ja 
n=1000/HHS) 75 vuotta täyttäneistä kuopiolaisista.  
 Yleisimmin käytetty lääkeryhmä oli sydän- ja verisuonisairauksien lääkkeet. Tutkimusaikana 
antitromboottisten lääkkeiden, vitamiinien ja kivennäisaineiden käytön havaittiin lisääntyneen. Iäkkäillä 
oli käytössä keskimäärin seitsemän lääkettä vuosina 1998 ja 2004. Muutoksia oli tapahtunut lääkityksen 
sisällössä: säännöllisesti käytössä olevien lääkkeiden ja vitamiinien/kivennäisaineiden keskimäärä 
lisääntyi ja tarvittaessa käytettävien lääkkeiden keskimäärä väheni. Laitoshoidossa olevat käyttivät 
keskimäärin kolme lääkettä enemmän kuin kotona asuvat iäkkäät. Joka neljännellä iäkkäällä havaittiin 
merkittävä monilääkitys (10+ lääkettä) ja joka kolmannella monilääkitys (6–9 lääkettä).  Jakaumassa ei 
tapahtunut muutoksia vuosien 1998 ja 2004 välillä. Sen sijaan ikäännyttäessä merkittävästi 
monilääkittyjen osuus kasvoi.  
 Tutkimuksessa havaittiin, että monilääkitykseen ja merkittävään monilääkitykseen yhteydessä 
olevat tekijät eivät ole yhtenäisiä, mitä ei ole raportoitu aikaisemmissa tutkimuksissa. Naissukupuoli ja 
korkea ikä olivat yhteydessä pelkästään merkittävään monilääkitykseen. Huonon itsearvioidun 
terveydentilan yhteys sekä monilääkitykseen että merkittävään monilääkitykseen oli vahva. 
Tutkimuksessa havaittiin, että yhtä diagnosoitua sairautta kohden käytössä olleiden lääkkeiden määrä 
oli suuri. Astma/COPD, sydänsairaus, diabetes, masennus ja kipu olivat sairauksia/oireita, jotka olivat 
yhteydessä monilääkitykseen ja merkittävään monilääkitykseen. Ikääntyneen yleinen huonontunut 
terveystilanne oli nähtävissä merkittävän monilääkityksen, huonontuneen ravitsemustilan, 
toimintakyvyn laskun ja heikentyneen kognition kasaantumisena. Tutkimus osoitti myös merkittävän 
monilääkityksen, mutta ei monilääkityksen, olevan kuolleisuuden indikaattori.  
 Tämä tutkimus osoitti monilääkityksen ja merkittävän monilääkityksen olevan yleistä. Lääkitys 
kasautuu erityisesti yleiskunnon suhteen haavoittuvassa tilassa oleville. Tulokset tukevat ajatusta 
säännöllisten lääkitysarviointien sisällyttämistä kiinteäksi osaksi moniammatillisesti toteutettua 
iäkkäiden kokonaisvaltaista hoitoa. 
 
Yleinen suomalainen asiasanasto: lääkkeet - käyttö; lääkehoito; polyfarmasia; ravitsemus; kognitio; 
toimintakyky; terveydentila; kuolleisuus; pitkittäistutkimus; ikääntyminen; ikääntyneet; vanhukset; 
Suomi
VIII 
 
 
 
 
  
IX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Set your goals high, and don’t stop until you get there 
- Bo Jackson 
 
  
                                 © Juba Production Oy 
X 
 
 
 
 
  
XI 
 
 
 
Acknowledgements 
This research was conducted at the Faculty of Health Sciences, University of 
Eastern Finland, in collaboration between the School of Pharmacy (Social 
Pharmacy) and the School of Medicine (Institute of Public Health and Clinical 
Nutrition) during the years 20052011. I sincerely thank all those who have 
contributed to or otherwise participated in my research work during these 
years. 
I am deeply grateful to my principal supervisor, Professor, Head of 
Research Hannes Enlund, PhD, for his invaluable advice, patient guidance and 
generous support throughout my research work. Your admirable enthusiastic 
attitude to science and unique ability to see things in a wider context has been 
essential for the completion of this thesis. I really feel fortunate for having had 
such a guide during this journey in the fascinating world of science.  I wish to 
thank my other supervisor, Professor Sirpa Hartikainen, MD, PhD, for her 
generous guidance in geriatric research along the way. I am also thankful for 
all your comments and other valuable contributions to this research, including 
financial resources. I express my thanks to the Head of Social Pharmacy, 
Professor Riitta Ahonen, PhD, for providing me a possibility to conduct 
postgraduate studies in her unit.  
The reviewers of this thesis – Docent Anders Carlsten, DMSc and Associate 
Professor Rob Heerdink, PhD – are acknowledged for their expert insight, 
constructive criticism and clarifying comments that helped to improve the 
content. I warmly thank Docent Harriet Finne-Soveri, MD, PhD, for agreeing 
to be my opponent in the public examination of this thesis. I also thank Anna 
Vuolteenaho, MA, for her skilful work in revising the English language of this 
summary. 
All co-authors are deeply thanked for collaboration and acknowledged for 
their important inputs to my research project. In particular, statistician Piia 
Lavikainen, MSc, deserves my sincere thanks for her never-ending patience in 
dealing with my statistical problems and trying to make me understand tricky 
analysis. I am also grateful to Professor Raimo Sulkava, MD, PhD, for his 
efforts in organizing the Kuopio 75+ and the GeMS studies and allowing me to 
use these datasets in this thesis. I owe warm thanks to Research Director 
Maarit Korhonen, LicSci (Pharm), PhD, for always keeping door open for me 
to consult her on epidemiological issues and to discuss other important topics 
of life during these years. 
XII 
 
 
 
I wish to thank all my colleagues and friends in the university for creating 
such an inspiring work environment and for sharing all kinds of feelings 
during this exciting ride on the rollercoaster of science. Members of the Gerho 
research group are acknowledged for interesting discussions on various topics 
in the field of ageing research. Thanks are also due to the entire staff based in 
the corridors of Social Pharmacy and Public Health. Research secretaries Päivi 
Heikura and Paula Räsänen and Secretary Sonja Rissanen are thanked for 
offering me kind assistance and help in practical matters every time I needed 
their expertise. Pharmacy owner, Docent Petra Vidgrén is thanked for offering 
me work shifts in her pharmacy. I really appreciate this opportunity to 
maintain my pharmacy skills besides research work. 
All the support that my nearest workmates have generously offered me has 
been invaluable. I want to express my most sincere thanks to Eija Lönnroos, 
MD, PhD, Maria Rikala, MSc, Jenni Ilomäki, MSc, Marja-Liisa Laitinen, MD, 
and Annika Männikkö, BSc, MPH, for all the great times I have spent with 
you. I also wish to thank Jaakko Mursu, PhD, and Anu Ruusunen, MSc, for 
nourishing my mind with refreshing discussions about science and life during 
the last stages of this thesis. Special thanks belong to Jaska for providing me 
really valuable peer support and advice even overseas.  
The countless hours that I have spent enjoying good company and various 
sport activities have kept me sane during this project. My floorball friends, 
both men and women, deserve thanks for good passes and other cheerful 
moments. Specific thanks to Miia Kovalainen, MSc, for sharing a great number 
of bruises in the playing field and outside of it, and to Professor Kristiina 
Järvinen, PhD, for encouraging sauna discussions after the games. Thanks also 
belong to Tarja and Antti for keeping me in shape – both physically and 
mentally. It is also a delight to have good “old” friends like you Heidi, Mari 
and Tiina. Our moments of relaxation and laughter, your devoted and long-
lasting friendship and discussions about life outside the world of science have 
meant a lot to me.  
I heartily thank Päivi Tuikkala for such a unique friendship and all those 
great, hilarious and memorable times that we have lived through together 
during our studies. Knowing that you are always ready to share all ups and 
downs of science and life has meant more to me than I can ever put into 
words. But one thing is sure – I would not have survived all this without you.  
I owe my warmest thanks to my parents, Eini and Osmo, for their 
enormous support throughout my life. You have given me and my brother 
Jussi the best resources for life that we ever could have got. My father always 
encouraged me to reach my study goals and he was so looking forward to 
seeing my dissertation day. Unfortunately life had other plans on a beautiful 
day in August. Now, a fond memory of my father, to whom I want to dedicate 
this thesis, will always live in my mind, now and forever in my heart.  
XIII 
 
 
 
My doctoral student position in the Ageing, Wellbeing and Technology 
Graduate School provided me financial support, but above all a deeper insight 
into the field of gerontology. Other financial support was obtained from the 
Clinical Drug Research Graduate School, the Jenny and Antti Wihuri 
Foundation, the Finnish Cultural Foundation (Central Fund and North Savo 
Regional Fund), the Orion-Farmos Corporation, the Kuopio University 
Pharmacy, the University of Eastern Finland, the La Carita Foundation, 
Societas Gerontologica Fennica, the Association of Finnish Pharmacies, the 
Finnish Pharmacists’ Association and the Finnish Pharmacists’ Society. Grants 
for printing costs from the Savo Society of Local Pharmacies and the Finnish 
Pharmaceutical Society are also acknowledged with gratitude.  
 
Kuopio, February 2011 
 
Sisulla ja sydämellä,  
 
 
 
Johanna Jyrkkä 
 
 
  
XIV 
 
 
 
 
XV 
 
 
 
List of Original Publications 
 
This thesis is based on the following original publications, referred to 
in the text by Roman numerals I–IV. Some unpublished data are also 
presented.  
 
I  Jyrkkä J, Vartiainen L, Hartikainen S, Sulkava R, Enlund H. 
Increasing use of medicines in elderly persons: a five-year follow-
up of the Kuopio 75+ Study. Eur J Clin Pharmacol 62:151–158, 2006 
 
II  Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S.  
Patterns of drug use and factors associated with polypharmacy 
and excessive polypharmacy in elderly persons. Results of the 
Kuopio 75+ Study: a cross-sectional analysis. Drugs Aging 26:493–
503, 2009 
 
III Jyrkkä J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. 
Association of polypharmacy with nutritional status, functional 
ability and cognitive capacity over a three-year period in an 
elderly population. Pharmacoepidemiol Drug Saf (in press, published 
online, DOI: 10.1002/pds.2116) 
 
IV Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S.  
Polypharmacy status as an indicator of mortality in an elderly 
population. Drugs Aging 26:1039–1048, 2009 
 
  
XVI 
 
 
 
 
 
 
  
XVII 
 
 
 
Contents 
 
1 Introduction 1 
2 Ageing and Polypharmacy 3 
2.1 Ageing person 3 
2.2 Definitions of polypharmacy 4 
3 Epidemiology of Polypharmacy 6 
3.1 Type of drugs used 6 
3.2 Quantity of drug use 12 
3.3 Prevalence of polypharmacy 22 
4 Factors Associated with Polypharmacy 29 
4.1 Sociodemographic factors 29 
4.2 Health-related factors 33 
4.3 Use of health services and patient adherence 37 
4.4 Mortality 39 
5 Summary of the Literature 41 
6 Aims of the Study 45 
7 Materials and Methods 46 
7.1 Kuopio 75+ Study 47 
7.1.1 Study population 47 
7.1.2 Data collection 50 
7.2 Geriatric Multidisciplinary Strategy for the Good Care of 
 the Elderly (GeMS) Study 51 
7.2.1 Study population 51 
7.2.2 Data collection 53 
  
XVIII 
 
 
 
 
7.3 Comparisons between the Kuopio 75+ Study and the  
 GeMS Study 54 
7.3.1 Cohorts of persons aged 75 years and older 54 
7.3.2 Follow-up of survivors 55 
7.4 Definitions and measures 56 
7.4.1 Drug use 56 
7.4.2 Polypharmacy status 57 
7.4.3 Main outcome measures 57 
7.4.4 Other measures 59 
7.5 Statistical analysis 61 
7.6 Ethical issues 63 
8 Results 64 
8.1 Content of medication 64 
8.1.1 Types of drugs used over time 64 
8.1.2 Ageing and the types of drugs used 66 
8.2 Quantity of drug use 68 
8.2.1 Number of drugs in use over time 68 
8.2.2 Ageing and the quantity of drugs used 70 
8.3 Characteristics of polypharmacy 74 
8.3.1 Polypharmacy over time 74 
8.3.2 Ageing and polypharmacy 76 
8.4 Correlates of polypharmacy 77 
8.4.1 Demographic factors and health status 77 
8.4.2 Diseases 77 
8.4.3 Nutritional status, functional ability and cognitive capacity 79 
8.5 Polypharmacy and mortality 81 
8.5.1 Mortality over a five-year period 81 
8.5.2 Indicators of mortality 81 
9 Discussion 85 
9.1 Methodological considerations 85 
9.1.1 Study populations 85 
9.1.2 Study design and data collection 86 
  
XIX 
 
 
 
9.2 Temporal trends in drug use and polypharmacy 88 
9.2.1 Changes in the types of drugs used 88 
9.2.2 High number of drugs in use 90 
9.2.3 Increasing occurrence of polypharmacy 92 
9.3 Polypharmacy and its correlates 92 
9.3.1 Sociodemographic correlates of polypharmacy 92 
9.3.2 Relevance of diseases and symptoms for polypharmacy 93 
9.3.3 Polypharmacy relation with health status and its determinants 94 
9.3.4 Polypharmacy as an indicator of mortality 96 
9.4 Polypharmacy in medical practice 98 
10 Conclusions 101 
11 Implications for the Future 103 
11.1 Practical implications 103 
11.2 Future directions for research 104 
12 References 105 
 
Appendices  
 
Original Publications  
  
XX 
 
 
 
 
  
XXI 
 
 
 
Abbreviations 
ACE Angiotensin-converting enzyme 
ADL Activities of Daily Living 
AHFS American Hospital Formulary System 
APA American Psychiatric Association 
ASA Acetylsalicylic acid (Aspirin®) 
AT1 Angiotensin II Type 1 
ATC Anatomic Therapeutic Classification  
ANOVA Analysis of variance 
BMI Body mass index 
BNF British National Formulary 
CI Confidence interval 
CNS Central nervous system 
COPD Chronic obstructive pulmonary disease 
CVDs Cardiovascular diseases 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders 
(4th edition) 
EUROCODE European Collaboration of Dementia 
EPP Excessive polypharmacy (10 or more drugs) 
FCI Functional Comorbidity Index 
GI Gastrointestinal 
GeMS Geriatric Multidisciplinary Strategy for the Good Care 
of the Elderly  
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme-A 
HR Hazard ratio 
IADL Instrumental Activities of Daily Living 
MMSE Mini-Mental State Examination 
XXII 
 
 
 
MNA Mini Nutritional Assessment 
MNA-SF Mini Nutritional Assessment (short form) 
NOMESCO Nordic Medico-Statistical Committee 
NPP Non-polypharmacy (0–5 drugs) 
NSAIDs Non-steroidal anti-inflammatory drugs 
OR Odds ratio 
OTC Over-the-counter 
PASW Predictive Analytics SoftWare 
PP Polypharmacy (6–9 drugs) 
PPIs Proton-pump inhibitors  
Rx Prescription  
SEP Socioeconomic position 
SII Social Insurance Institution 
SPSS Statistical Package for the Social Sciences 
SD Standard deviation 
SE Standard error 
UK United Kingdom 
US United States  
USD United States dollar 
WHO World Health Organization 
 χ2 Chi-squared 
  
XXIII 
 
 
 
Definitions of Key Terms 
Community-dwelling 
This term is used when referring to elderly persons who are not in 
assisted living (incl. nursing homes, residential care homes, hospitals 
and other types of institutional accommodations). 
 
Drug  
Means all chemical substances used in diagnosis, prevention and 
treatment of diseases.  
 
Drug use  
This term refers generally to all drugs belonging to a person’s drugs 
treatment. In the results section, drug use refers to regularly and as-
needed consumption of drugs, vitamins and mineral supplements 
(excluding herbals) the participants were using at the time of interview. 
 
Elderly person  
In the literature review, all publications concerning elderly 
populations (mostly reached the age of 65 years) are taken into account. 
In the results section, the age of 75 years and older is used as definition 
of an elderly person. 
 
Over-the-counter (OTC) drugs  
Drugs available in pharmacies without prescription. Another 
commonly used term is non-prescription drugs.  
 
Polypharmacy  
There is no accepted consensus on the definition of polypharmacy. 
Generally it refers to the use of multiple drugs concomitantly. In 
studies using quantitative definitions, five or more different drugs is 
most frequently used as a cutoff. 
 
  
XXIV 
 
 
 
Polypharmacy status  
Excessive polypharmacy (EPP) is defined as the use of ten or more 
drugs. Polypharmacy (PP) is used when referring to persons using six 
to nine drugs. The non-polypharmacy (NPP) group includes persons 
using five or fewer drugs.  
 
Population-based 
Studies using a population-based sample of elderly persons as a study 
cohort have included the entire elderly population, including both 
independently living and assisted living (incl. nursing homes, 
residential care homes, hospitals and other types of institutional 
accommodations) elderly persons. 
 
Prescription (Rx) drugs  
Drugs dispensed from pharmacy only by a prescription from a 
physician.  
  
 
 
 
 
1 Introduction 
There has been great attention on drug treatment of elderly persons in 
health care. Today, increasing polypharmacy is considered a major 
public health issue among elderly persons in many Western countries, 
including Finland. This is because elderly age groups, the greatest 
consumers of drugs, are the most rapidly growing segments of the 
population. In 2008, elderly persons aged 65 years and older accounted 
for 40% of all drug expenditure in Finland (1), while they constituted 
only 17% of the total population (2). The estimates of population 
forecast show that the proportion of this age group will increase to 
23% in Finland by 2020, and is going to reach 29% by 2060 (3). It is 
obvious that this will pose a challenge to the Finnish society in coping 
with the care of these ageing populations in the near future.  
Ageing is an inevitable and constant process that changes the 
composition of the body and makes it physiologically less able to 
function (4,5). These declines affect all organs and processes in the 
body to a varying degree, leading to altered pharmacokinetics and 
pharmacodynamics of many drugs. This makes the management of 
drug treatment difficult in elderly persons. Concerns about 
polypharmacy are mainly due to its associations with undesirable 
health outcomes. It has been widely shown that polypharmacy 
increases the risk for adverse drug events (6-11). More challenges in 
drug handling are confronted by the wide individuality of ageing 
processes. Despite these risks, avoiding polypharmacy is not always 
reasonable in elderly persons, as many of them have several diseases 
that require drug treatment. Finding the right balance between benefits 
and harms of the drugs used define the quality of overall drug 
treatment. 
2 
 
 
 
The reasons for the increasing occurrence of polypharmacy over the 
past decades are various. As a result of an extended life expectancy, 
elderly persons suffer more and longer from diseases requiring drug 
treatment than before. Hence, age-related morbidity is one of the most 
potent reasons for increasing drug use. Another reason might also be 
the new pharmacotherapies launched to treat diseases and relieve 
symptoms typical for elderly persons, such as Alzheimer’s disease and 
osteoporosis (12). Moreover, the use of preventive drugs, such as 
antithrombotic agents, cholesterol-lowering drugs and 
calcium+vitamin D preparations, has become more common during 
the past decades (13-15).  
Review of literature shows that there is a clear need for research 
describing current state of drug use and longitudinal changes 
occurring in the drug treatment of elderly persons. In addition, 
previous research has mainly concentrated on sociodemographic 
correlates of polypharmacy, but the role of different kinds of health-
related factors for polypharmacy is poorly studied. This study 
provides a general overview of drug use and polypharmacy among 
elderly Finnish persons. More specifically, the study aimed at 
assessing drug use by describing longitudinal changes occurring in the 
type of drugs used, the mean number of drugs in use and the 
prevalence of polypharmacy. In addition, associations of 
polypharmacy with demographics, diseases and other health-related 
factors were determined. Knowledge on the implementation of drug 
treatment is relevant for health care personnel when trying to optimise 
drug treatment of elderly persons. For policy makers, this study gives 
insights for future needs in the care of elderly persons. 
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2 Ageing and Polypharmacy  
The exact age at which a person becomes old is impossible to define 
due to a wide variety in the process of ageing. There are also problems 
related to the term polypharmacy, which has been defined in several 
different ways. The definition depends on which aspect we want to 
emphasize; the quantitative or qualitative indicators of medication. 
2.1 AGEING PERSON 
Ageing is a complex process that affects different aspects of life. In 
literature, ageing is commonly defined from biological, psychological 
and social points of view (16). Biological ageing refers to a gradual 
deterioration of the human organism leading to overall frailty in body 
and decline in function with age. This increases the risk of diseases and 
other physical disabilities (17). Psychological ageing concern the changes 
that occur in sensory and perceptual processes, adaptive capacity to 
new situations, personality and different divisions of mental function, 
such as memory, learning and intelligence (18). Social ageing covers 
elderly persons’ altering social roles and relationships as members of 
different social groups. The social context has a fundamental role in 
determining the experience of ageing for elderly persons. 
Conventionally, a chronological calendar age of 65 years and older 
is used when referring to elderly persons (19). In Finland, as in many 
other Western countries, this age is equivalent to the retirement age, 
and thus commonly used as a cut-off point in national statistics (20,21). 
However, this simple way to define elderly persons is not that 
straightforward, as chronological age seldom correlates with biological 
age. Today, many retired persons are fairly healthy and in good 
condition, and because of this they do not perceive themselves as old. 
This has taken place over decades as a result of improved life facilities 
and treatment patterns leading to prolonged life expectancy. 
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In the field of ageing research, increasing healthy life years have 
meant considerable changes in the concept of an elderly person. The 
previously used threshold of 65 years has been replaced with 75 years 
and older. This trend can be argued by the commonly agreed fact that 
the impact of the ageing process is usually first experienced around the 
age of 75 years (22). Thus, it is reasonable to assume the chronological 
definition of 75 years to be as close as possible to the present reality. 
2.2 DEFINITIONS OF POLYPHARMACY 
There is no generally accepted consensus on the definition of 
polypharmacy, except that it indicates the use of multiple drugs by a 
single patient (23-26). This has resulted in a wide variety of definitions 
occurring in the literature, making it difficult to compare study results. 
Polypharmacy is most commonly defined quantitatively by a specific 
number of drugs in use, but also qualitatively definitions, in reference 
to the quality of drug treatment, are used (27,28). Based on a review 
article, it seems that European studies prefer the number of drugs in 
defining, whereas US studies often define polypharmacy according to 
whether a medication is clinically indicated or not (24).  
In studies applying a quantitative definition, five or more different 
prescribed drugs is most frequently used as a cutoff (29-49). Some 
studies have used the same cutoff point, but have also included OTC 
drugs when counting the total number of drugs in use (9,14,50–63). A 
couple of studies have distinguished between minor polypharmacy 
(concurrent use of two to four prescribed drugs) and major 
polypharmacy (concurrent use of five or more prescribed drugs) (64-
66).  
With regard to excessive polypharmacy, a separate definition for it 
has been used in studies published during the 2000s.  Excessive 
polypharmacy is most commonly defined as the use of ten or more 
drugs (34,44,46,48,63,67–69). Besides excessive polypharmacy (44), 
other terms used when referring to the use of ten or more drugs are 
high-level polypharmacy (49,70) and major polypharmacy (46). The 
term excessive polypharmacy was used for the first time in the mid-
1980s in a book concerning rational use of drugs for elderly persons 
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published by the WHO (71). However, it did not state any specific 
number of drugs that can be regarded as excessive polypharmacy. 
According to the most commonly used qualitative definition, 
polypharmacy is present when more drugs have been administrated 
than is clinically indicated (24). Several other different qualitative 
definitions are also used, such as inappropriate medication, 
duplication of drugs and drug/drug interactions (72). In fact, it can be 
concluded that all qualitative definitions have something to do with 
the appropriateness of overall medication.  
Quantitative definitions are used much more commonly compared 
to qualitative ones. Thus, the studies included in the literature review 
focus mainly on those defining polypharmacy quantitatively.  
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3 Epidemiology of 
Polypharmacy 
Epidemiological studies on drug use in elderly populations have 
usually been conducted in cross-sectional settings. To date, only few 
studies have reported longitudinal changes in drug use for a certain 
cohort of elderly persons (51,66,73-76). Other studies describing the 
changes in drug use over time have made comparisons between 
separate cross-sectional age cohorts at different time points 
(13,14,51,77-80). This chapter summarizes studies published over the 
past decades on type of drugs used, quantity of drug use and 
prevalence of polypharmacy among elderly populations. An extensive 
search of literature for relevant papers concerning polypharmacy was 
done, but it did not follow the strict rules of a systematic review.  
3.1 TYPE OF DRUGS USED 
The nature of medication is usually described by presenting 
pharmacological substances that elderly persons are using most 
frequently (73,81-83). Another common way is to use specific drug 
classification systems in which upper levels are based on therapeutic 
categories of drugs. In terms of classifications, the most commonly 
used is the ATC classification, which is maintained by the WHO 
Collaborating Centre for Drug Statistics Methodology (84). Other 
classifications used are the BNF in British studies (85,86) and the AHFS 
in US studies (33,43,87). This chapter describes the changes which 
occurred over time in five most commonly used drug classes by 
elderly persons. 
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Cardiovascular drugs 
For decades, cardiovascular drugs have remained the most commonly 
used category of drugs in elderly persons (35,63,83,88-90). Despite the 
fact that over the past decades new drug choices have been launched 
on the market for the treatment of cardiovascular diseases (CVDs), no 
remarkable change can be observed in the prevalence of the use of 
cardiovascular drugs over time.  
A population-based Swedish study reported that one in every three 
(33%) of those aged 70 years and older used cardiovascular drugs at 
the beginning of the 1970s (13). The corresponding prevalence was 36% 
among community-dwelling US elderly persons aged 63 years and 
older (91). Most studies on elderly persons from the 1980s reported 
prevalences between 40% and 80% for the use of cardiovascular drugs 
(79,92-95). Based on a Swedish study, in the late 1980s one in three 
(31%) persons aged 75 years and older used cardiovascular drugs (96). 
Over this decade, hypertension and heart diseases were the most 
common conditions for which elderly persons used prescription drugs 
(97). The prevalence remained high (46–77%) in most studies 
conducted in the 1990s (43,53,79,80,98,99). However, some lower 
prevalences were also observed: 29–32% for Taiwanese (78), 37–47% 
for Swedish (34,100), 38% for Italian (52) and 43% for English (55) 
elderly populations. During the 2000s, a prevalence of 71% was 
reported for community-dwelling Italian persons aged 65 years and 
older (101). In studies conducted in hospital and nursing home settings 
the prevalence has varied between 55% and 69% (40,49,70).  
In treatment of various heart conditions, including cardiac 
arrhythmia and congestive heart failure, cardiac glycosides were 
frequently used (14–22%) in the 1970s and 1980s (29,58,73,94,100,102), 
but since then, the prevalence has decreased (4–14%) in most countries 
(13,40,67,80,103). Diuretics and β-blocking agents have maintained 
their position as common cardiovascular medication over decades. 
Since the 1980s, the prevalence of the use of diuretics has varied 
between 11% and 35% (33,58,80,92,96,101,104). Correspondingly, 
prevalences between 7% and 28% have been reported for the use of β-
blocking agents (13,58,85,94,100,105). Besides these traditional drugs, 
several new drugs have been adopted during the 1990s and 2000s as 
part of cardiovascular drug treatment of elderly persons. These 
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include ACE inhibitors, AT1 receptor antagonists, calcium channel 
blockers and lipid modifying agents (13,14,106). In the beginning of the 
2000s, a study of community-dwelling Italians aged 65 years and older 
reported the prevalence of 32% for the use of ACE inhibitors and 12% 
for AT1 receptor antagonists (101). The prevalence for the use of ACE 
inhibitors was 14% among a population-based Swedish study of those 
aged 77 years and older examined in 2002 (105). Slightly higher 
prevalences have been reported for the use of calcium channel blockers 
(23–51%) (49,101,106), whereas the proportion of persons using lipid 
modifying agent has varied between 12% and 27% during the 2000s 
(49,101,106,107).  
Some studies have examined cardiovascular medication among 
those having polypharmacy or excessive polypharmacy. One Swedish 
study reported β-blockers (49%) and lipid-modifying agents (42%) to 
be the most prevalent cardiovascular drugs among those elderly 
persons who use five or more drugs (62). A US study examining those 
using nine or more drugs concomitantly reported a prevalence of 35% 
for the use of diuretics and 24% for the use of ACE inhibitors in a 
nursing home setting (108).  
 
Drugs for the nervous system 
Over time a clearly increased prevalences can be observed for the use 
of drugs acting on the central nervous system (CNS) in elderly 
populations. In the 1970s and 1980s, these drugs were used by 14–25% 
of those aged 65 years and older, based on studies of population-based 
samples and community-dwelling elderly populations (13,92,93). For 
similar populations, slightly higher prevalences (24–37%) were 
reported in the 1990s (34,35,55). With regard to psychotropic use, a 
Finnish study conducted in the late 1990s found a prevalence of 37% 
for community-dwelling persons aged 75 years and older (109). In US 
nursing homes two-fifths (65%) were using psychotropics in the mid-
1990s (99). An Italian study conducted in the 2000s reported a 
prevalence of 17% for the use of psychotropics among a community-
dwelling elderly population (101). In the US, half (46–49%) of those 
aged 65 years and older used CNS drugs in studies conducted in 
community-dwelling (43) or home care settings (90). Of elderly 
hospital patients and nursing home residents, 23–57% used CNS drugs 
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in the 2000s (49,70,87). In Australian nursing homes 54% were using 
psychotropics (40). 
The most commonly used psychotropics are hypnotics and 
sedatives. According to Swedish population-based studies, 10–26% of 
elderly persons were using these drugs during the 1980s and 1990s 
(13,14,96,100,110). Over the same time period, lower prevalences (4–9%) 
were reported for US and British elderly populations (31,92,104). In the 
2000s, the prevalence was 11% in Italy (101) and 17% in Sweden (14). 
In Swedish nursing homes up to 55% of residents were found to be 
using hypnotics and sedatives (111). Of demented Australians, every 
fourth (28%) was a user of these drugs (112).  For the use of anxiolytics 
5–14% prevalences have been reported in studies of population-based 
samples and community-dwelling elderly since the 1980s 
(31,92,96,100). The most common class of anxiolytics is 
benzodiazepines, which were used by 17% of Irish community-
dwelling elderly persons in the mid-1990s (113). Almost half (46%) of 
nursing home residents using five or more drugs concomitantly used 
anxiolytics (62). Also antidepressants are widely used, showing 
prevalences between 3% and 12% for population-based and 
community-dwelling elderly populations since the 1980s 
(14,31,64,92,94).  
 
Analgesics and antipyretics 
Analgesics and antipyretics have been one of the most commonly used 
drug groups over the decades (29,68,74,83,89,108,114). Studies from the 
1970s (13,63,91,102,115-117) and 1980s (31,88,92,94,104,118) have 
consistently reported prevalences of 16–32% for the use of analgesics 
among community-dwelling and institutionalized elderly populations. 
Slightly higher prevalences (28–57%) were reported in the 1990s 
(13,14,64,78,103). The prevalences remained high (47–72%) in studies 
conducted in the 2000s (13,40,111). The highest prevalence was 
observed among US home care patients (90) and the lowest among 
Indian hospital patients  (49). A recent Finnish study showed that 45% 
of those aged 75 years and older were using analgesics daily or on an 
as-needed basis (119). When analysing only those using five or more 
drugs, 21% were users of analgesics and antipyretics (62). Almost half 
(46%) of the nursing home residents having nine or more drugs in use 
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used analgesics (108). Overall, these prevalence comparisons between 
different studies need to be interpreted with caution, because some 
studies had information only on prescribed analgesics, whereas others 
had also included analgesics purchased as over-the-counter drugs.  
Paracetamol and NSAIDs are the most commonly used analgesics 
(54,63,114,119). According to the population-based Sloane study, 
paracetamol is used by every third (30–39%) and ASA by every fifth 
(17–23%) elderly Americans aged 65 years and older (67,68). A higher 
prevalence for the use of paracetamol (48%) was observed among 
elderly Finnish persons aged 75 years and older (119). For the use of 
NSAIDs, prevalences of 5–15% have been reported during the 1980s 
and 1990s (33,54,58,100,110). Thereafter, prevalences of 20–30% have 
been reported (119-121). In a Swedish population-based study, every 
fifth (21%) of those using five or more drugs concomitantly had 
NSAIDs or other antirheumatic products in their regimen (62). A US 
study of community-dwelling elderly reported separately a prevalence 
of 25% for the use of prescription NSAIDs and 41% for the use of over-
the-counter NSAIDs (122). For the use of opioids, quite consistent 
prevalences (4–14%) have been reported over decades for population-
based samples and community-dwelling elderly persons 
(14,58,80,100,110, 119,121,122). 
 
Drugs for alimentary tract and metabolism 
Among community-dwelling elderly persons, 18–34% have been 
reported to use drugs for alimentary tract and metabolism in studies 
conducted during the 1990s (34,52,80,95). The corresponding 
prevalences for hospital patients and nursing home residents have 
been remarkably higher (84–90%) (40,49). The most frequently used 
drugs belonging to this therapeutic category are drugs for 
gastrointestinal (GI) problems, vitamins, mineral supplements and 
drug for diabetes mellitus (74,80,90). 
GI drugs are used by 10–31% of population-based samples and 
community-dwelling elderly persons, showing no remarkable change 
over decades (43,53,88,93,94,101,117). For similarly defined 
populations, the proportion of those using laxatives (4–17%) has 
remained at the same level since the 1970s (14,30,85,96,97,117,123). Of 
elderly hospital patients, 21–27% are using laxatives (54,102,118). 
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Among nursing homes patients the prevalences have been between 
60–70% (40,103,111). Another commonly used group of GI drugs is 
antacids and proton pump inhibitors (PPIs), most studies reporting 
that 4–17% of elderly persons use some drugs for acid-related 
disorders (14,33,58,64,80,116). According to a Swedish study, 30% of 
those with polypharmacy (five or more drugs) use drugs for acid-
related disorders (62). A recent study of Austrian hospital patients 
found that 37% of those aged 75 years and older had PPIs in use (107).  
The estimates on the use of vitamins and mineral supplements are 
rather inconsistent. Based on the recent Sloane study, 58% of elderly 
Americans aged 65 years and older are using some vitamins (68). 
Italian studies from the 2000s revealed remarkable differences in the 
prevalence of vitamin use between community-dwelling (5%) (101) 
and hospitalized (45%) (121) elderly persons aged 65 years and older. 
A recent study of Finnish nursing homes reported that 33% of the 
residents were receiving vitamin D supplementation and 28% calcium 
supplementation (124).  
 
Blood and blood-forming organs 
The use of drugs for blood and blood-forming organs has become 
common in the 1990s. Over this period the highest prevalences (23–
39%) for the use of these drugs were observed in Nordic studies of 
community-dwelling elderly persons (34,53,80). The corresponding 
prevalences were reported to be   6% for Italian (52) and 8% for elderly 
US populations (43). Studies conducted in US nursing homes found 
every fifth (18%) resident to be using drugs for blood and blood 
forming organs (99). Over a ten-year period from 1992 to 2002, the 
prevalence increased from 3% to 43% among those aged 77 years and 
older (14). Other studies conducted in the 2000s have found a 
prevalence of 46% for Australian nursing home residents (40) and 53% 
for hospitalized elderly persons in India (49). 
The observed increase in the use of drugs for blood and blood-
forming organs during the past two decades is mostly due to increased 
use of antithrombotic agents as part of elderly persons’ medication. 
Before the 1990s, the use of antithrombotics was rare, as only a couple 
of percent of elderly persons were using these drugs (13,79,92). 
Thereafter, most studies have reported remarkably higher percentages 
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(16–43%) for the use of antithrombotics (13,14,40,103). Based on a 
recent study, antithrombotics were used by half (52%) of those having 
five or more drugs in use concomitantly (62). 
3.2 QUANTITY OF DRUG USE  
Over the past 40-year period, the mean number of drugs in use in 
studies conducted for population-based (incl. independently and 
assisted living persons) and community-dwelling (incl. independently 
living persons) samples of elderly persons has increased clearly (Table 
1, Table 2). Similarly, an increasing number of drugs in use over time 
can be observed among institutionalized elderly persons (Table 3). In 
general, it seems that in Nordic and US studies the reported mean 
numbers have been slightly higher than in other countries.  
 
Mean number of drugs in population-based samples and community-dwelling 
elderly persons  
A population-based study of British elderly persons reported a mean 
of 2.7 drugs in the late 1960s (125). Studies conducted during the 1970s 
reported a mean of slightly over three prescription drugs for Swedish 
(13,73) and Finnish (77) population-based samples of elderly persons. 
For community-dwelling elderly populations, these means have varied 
between 1.9 and 3.4 in studies conducted outside the Nordic countries 
(74,117,126,127). When counting both prescription and over-the-
counter drugs the mean number varied between 2.9 and 6.3 
(51,74,116,126,128). 
During the 1980s, the mean number of prescription drugs varied 
between 2.0 and 3.9 (74-77,92,94,104,129). When counting both 
prescription and over-the-counter drugs, means between three and 
four drugs were reported in Nordic (51,79,96,110) and US studies 
(74,76,92,104). In the 1990s, the reported means for the use of 
prescription and over-the-counter drugs was remarkably higher in 
Nordic countries (3.1–5.4) (53,59,79,80) compared to other countries 
(2.0–3.5) (52,55,58) 
Studies conducted during the 2000s have showed means between 
2.9 and 8.0 for the use of prescription drugs (38,43,44,47,48,90,101). Of 
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these, the highest ones were reported in US studies (43,90) and the 
lowest in Italian (101) and Irish (38) studies. When taking into account 
also OTC drugs, means have varied from 3.5 to 6.9 drugs (62,69,105).  
   
Mean number of drugs in elderly hospital patients and nursing home 
residents 
During the 1970s and 1980s, epidemiological studies on drug use in 
institutional settings were scarce (Table 3).  According to a Scottish 
study from the mid-1970s a mean of 3.3 prescription drugs was used 
by hospital patients aged 65 years and older (102). In the 1980s, 
corresponding means for the same aged institutionalized elderly 
persons were 3.3 in Ireland (118) and 4.0 in the US (130). In Norway, a 
mean of 5.5 prescription drugs was observed among nursing home 
residents (mean age 82 years) (50). Remarkably higher means (5.4–
10.4) were reported in studies conducted during the 1990s (9,54,60,131-
133). In Australian nursing homes in which the mean age of residents 
was around 80 years, the mean number of prescription drugs in use 
increased from 4.5 to 6.0 drugs during the 1990s (40). The 
corresponding mean was 7.7 drugs in Swedish nursing homes in the 
mid-1990s (103). 
In the 2000s, research on drug use in hospitals and nursing home 
has been more active (Table 3). Means between 4.8 and 7.5 for the use 
of prescription drugs have been reported in Japan (120) and some 
European countries (45,70,107,134). The highest means were reported 
in the US (8.0) (108) and Sweden (11.9) (111). Demented Australian 
nursing home residents used an average of 9.7 drugs, including 
prescription, over-the-counter drugs, vitamins, mineral supplements 
and herbals.  
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3.3 PREVALENCE OF POLYPHARMACY 
Since the 1970s, studies on drug use have reported the prevalence of 
polypharmacy for population-based samples and community-dwelling 
elderly persons (Table 1, Table 2), whereas the earliest reports for 
elderly hospital patients and nursing home residents are from the 
1980s (Table 3). Studies reporting polypharmacy show a wide range in 
prevalence estimates. Direct comparisons of prevalences between 
studies are difficult due to inconsistent definitions of drug use: some 
studies take into account only prescription drugs, while others include 
over-the-counter drugs, vitamins, mineral supplements and herbals. 
The importance of the time period under which data on drug use is 
collected was illustrated in a study that reported separately the mean 
number of prescription drugs used during the preceding two days 
(1.8), two weeks (2.2) and three months (2.6) (136).  
 
Polypharmacy in population-based samples and community-dwelling elderly 
persons 
According to a Swedish study, every fourth (26%) person aged 70 
years was using four or more prescription drugs concomitantly in the 
early 1970s (13). The corresponding prevalence was 34% among 
Finnish retirement home residents (149). Of community-dwelling 
elderly Americans, 18% were using five or more prescription drugs in 
the late 1970s. When taking into account both prescription and over-
the-counter drugs, the prevalence of the use of five or more drugs was 
13% for a population-based sample of elderly Finns aged 70–79 years 
(51). A somewhat higher proportion (23%) was found in a study of 
community-dwelling cohort of those aged 65 years and older (135).  
In the 1980s, US studies reported prevalences between 10% and 
18% for the use of five or more prescription drugs among persons aged 
65 years and older (33,92,97,150). Using the same definition of 
polypharmacy, a similar (10%) prevalence was also observed in 
England (31). Of Finnish elderly persons, every fifth (22%) was 
reported to use five or more prescription/over-the-counter drug at the 
end of 1980s (51). Seven or more prescription drugs were used by one 
in ten (8%) of those aged 70 years and older (129).  
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Epidemiological research on drug use of elderly persons increased 
remarkably during the 1990s (Table 1, Table 2). Over this decade, the 
lowest prevalences for the use of five or more prescription drugs 
among persons aged 65 years and older were reported in the 
Netherlands (2–4%) (66) and the UK (10%) (35). The corresponding 
prevalence was 39% for Swedish community-dwelling elderly persons 
of the same age (34). For Finnish elderly persons aged 65 years and 
older, the prevalence of the use of six or more prescription drugs 
showed an increase from 19% to 25% during the 1990s (80). When also 
taking into account over-the-counter drugs, the prevalence of the use 
of five or more drugs varied between 15% and 40% among persons 
aged 75 years and older living in European countries (14,52,53,55,59). 
US studies on persons aged 65 years and older have reported fairly 
high prevalences. Among women, 59% were reported to use five or 
more prescription/over-the-counter drugs (63). Furthermore, when 
including vitamins, mineral supplements and herbals as well, a 
prevalence of 63% was found in a population-based US study (67) 
In the 2000s the prevalences for polypharmacy in population-based 
samples and community-dwelling elderly persons were generally 
higher than in the previous decade (Table 1, Table 2). Large Swedish 
register-based studies reported that over half (52–57%) of those aged 
75 years and older were using five or more prescription drugs (42,44). 
For a population-based sample of Swedish elderly, the prevalence was 
42% when counting both prescription and over-the-counter drugs. The 
corresponding prevalence among those aged 70 years and older was 
54% in a German study (61). High prevalences (42–65%) have also 
been observed in other studies of prescription drug use among 
populations aged 65 years and older (38,43,47,48). The lowest 
prevalences concerning prescription drug use were reported in Asian 
countries: 12% for the use of five or more drugs in Taiwan (143) and 
36% for the use of six or more drugs in Japan (142). Using five or more 
drugs as a definition of polypharmacy, an US study reported a 
prevalence of 58% when including also vitamins, mineral supplements 
and herbals besides prescription and over-the-counter drugs (68). A 
recent study of Polish centenarians showed that one in three (33%) 
used five or more drugs prescription/over-the-counter drugs (151). In a 
European study the prevalence of polypharmacy, defined as the use of 
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six of more prescription/over-the-counter drugs, was estimated among 
home care elderly persons from eight different countries in the 
beginning of the 2000s (141). This study revealed that the highest 
prevalence of polypharmacy was seen in Finland (73%) and the Czech 
Republic (68%), whereas the lowest prevalences were found in Italy 
(36%), the Netherlands (35%) and Norway (34%) (Figure 1).  
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Excessive polypharmacy in population-based samples and community-
dwelling elderly persons 
The earliest estimates on excessive polypharmacy for population-
based samples and community-dwelling elderly persons are from the 
1990s (Table 1, Table 2). In a Swedish study of community-dwelling 
persons aged 75 years and older, 13% were found to use ten or more 
prescription drugs in the mid-1990s (34). Using the same cut-off point 
for excessive polypharmacy, a prevalence of 12% was found for 
persons aged 65 years and older in a US study that counted also over-
the-counter drugs, vitamins, mineral supplements and herbals besides 
prescription drugs (67). Among US women, a similar prevalence (12%) 
was observed for the use of ten or more prescription/over-the-counter 
drugs (63). An Italian study conducted in the early 1990s reported that 
11% of those aged 75 years and older were using seven or more drugs 
concomitantly (52).  
Studies conducted during the 2000s have reported prevalences 
between 11% and 20% for excessive polypharmacy, defined as the use 
of ten or more drugs (48,68,69). All of these studies included 
populations aged 65 years and older (Table 1, Table 2). Similar 
prevalences (10–18%) were found for the use of ten/eleven or more 
prescription drugs in Swedish register-based studies of populations 
aged 75 years and older (42,44).  
Studies examining drug use patterns in home care patients have 
reported remarkably higher prevalences of excessive polypharmacy 
than those using population-based samples or community-dwelling 
elderly persons (Table 1, Table 2). A US study showed a prevalence of 
39% for the use of nine or more prescription drugs (90), while the 
prevalence was 22% in a large European study that also included over-
the-counter drugs (141). Country-based prevalences showed that 
excessive polypharmacy was most common among Finnish (41%) and 
Czech (39%) elderly home care patients (Figure 1). The lowest 
proportions were found in Norway (11%) and Italy (7%).  
 
Polypharmacy in elderly hospital patients and nursing home residents 
Research on polypharmacy in institutionalized elderly persons was 
scarce before the 1990s (Table 3), with only a few articles reporting on 
the prevalence of polypharmacy among the US population aged 65 
years and older in the 1980s. According to these studies, two-fifths 
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(43%) were using four or more (130) and one-third (33%) five or more 
(32) prescription drugs in the late 1980s.  
In an Australian study comparing cross-sectional cohorts of nursing 
home residents the proportion of those using five or more prescription 
drugs increased from 42% to 64% during the 1990s (40). When taking 
into account prescription and over-the-counter drugs, high 
prevalences were also observed in other countries: 83% of Canadian 
(36) and 66–79% of US (39,54,60,132,153) elderly persons aged 65 years 
and older used five or more drugs concomitantly.  
When comparing the prevalences of polypharmacy reported during 
the 2000s, wide variation can be observed between countries. In 
Turkey only 17% of persons aged 60 years and older used five or more 
prescription/over-the-counter drugs (57). Japan was the other country 
where a low prevalence was observed, as 27% of the oldest old persons 
(aged 85 years and older) were using six or more prescription drugs. 
Studies conducted in European countries have reported 60–80% 
prevalences for polypharmacy defined as the use of four/five or more 
prescription drugs (45,121,147). In the early 2000s, the corresponding 
prevalence was 71% in Australian nursing homes (40). The highest 
prevalence for the use of five or more prescription drugs (90–91%) was 
among Indian hospital patients aged 60 years and older (49) and 
Australian demented nursing home residents aged 65 years and older 
(112).  
 
Excessive polypharmacy in institutionalized elderly persons 
US studies conducted in the 1990s revealed a prevalence of 21–38% for 
the use of nine/ten or more drugs among hospital patients aged 65 
years and older (9,39,54,60,132,153). In Canada, 46% of nursing home 
residents of the same age used nine/ten/eleven or more prescription 
drugs (36). In Italy, one in four (23%) elderly patients used seven or 
more drugs at discharge from hospital (146).  
In the 2000s, two-fifths (39%) of US nursing home residents aged 65 
years and older were using nine or more prescription drugs (108). Of 
Irish hospital patients aged 75 years and older, quite a low proportion 
(9%) was using ten or more prescription drugs (70). In Indian 
hospitals, the corresponding proportion was 45% for patients aged 60 
years and older (49). An Austrian study of hospital patients aged 75 
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years and older found a prevalence of 58% for the use of seven or more 
prescription drugs (107).  
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4 Factors Associated with 
Polypharmacy 
Research on the correlates of polypharmacy has been active over the 
past years. Studies have demonstrated several sociodemographic and 
some health-related and health care system related factors to be 
associated with polypharmacy in elderly persons. Furthermore, the 
outcomes of polypharmacy, such as appropriateness of medication 
(7,8,10), falls (37,154-156) and medical costs (139,157-160), have been 
targets of research more recently. This chapter describes both factors 
that influence polypharmacy and outcomes associated with 
polypharmacy. For some factors it is not clear whether they should be 
interpreted as determinants or consequences of polypharmacy. 
Prescriber-related factors were excluded from this review. 
4.1 SOCIODEMOGRAPHIC FACTORS 
Sex 
Several epidemiological studies examining drug use patterns of elderly 
persons have shown a higher proportion of women using some drugs 
than men (88,161). Furthermore, women consume a higher number of 
drugs than men (13,94,100,115,144,162). A recent Swedish register-
based study of elderly persons aged 75 years and older reported a 
significant correlation between sex and the mean number of 
prescription drugs in use (6.0 for women, 5.5 for men) (44). A US study 
observed women to be 32% (95% CI 8–62%) more likely to receive 
polypharmacy (five or more drugs) than men after adjustments (163). 
The risk proportion was similar (32%, 95% CI 31–33%) in Sweden (44). 
A slightly lower risk (16%, 95% CI 4–30%) was found in a British study 
using the same definition for polypharmacy (55). With regard to 
excessive polypharmacy, a register-based Swedish study reported a 
39% (95% CI 37–41%) increased risk of the use of ten or more drugs for 
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women (44). Besides the well-reported association with female sex, 
there is one recent study reporting no association between sex and 
polypharmacy (five or more drugs) (OR 1.03, 95% 0.69–1.55, ref. men) 
when using age, education, living status, marital status and 
comorbidity as adjusting variables (105) 
 
Age  
Generally, studies have shown increasing age to correlate positively 
with the total number of drugs in use (33,78,101) and the occurrence of 
polypharmacy (48,55,66,139,164). The increase in the number of 
prescription drugs has been estimated to be 0.4 drugs per 10 years of 
age in a study of elderly men living in South Wales (65). A study 
conducted in a nursing home setting in New Zealand found an 
increasing trend in the mean number of prescription drugs, while the 
mean of over-the-counter drugs decreased significantly with age (95). 
According to a recent Swedish register-based study, the prevalence of 
polypharmacy increases very rapidly after the age of 60 years (165). 
Another study analysing the influence of age on drug use suggest that 
the general observation of increasing use of drugs with age diminishes 
in the oldest old age group (64). This was also observed to some extent 
after the age of 90 years in the above mentioned Swedish study (165). 
According to a study presenting age-specific analyses, the occurrence 
of polypharmacy (five or more drugs) increased until the age of 90 
years and older (96). Similar results have been found in a Japanese 
study that reported decreasing prevalence for the use of six or more 
drugs with age: a significant difference in prevalences was observed 
between age groups 65–74 years (40.9%) and 85 years and older 
(30.6%) (142). A Swedish study revealed that the number of drugs 
increased up to the age of 90 years, after which the number of drugs 
begun to decrease (96) 
With regard to polypharmacy, after adjustments the probability of 
having polypharmacy (five or more drugs) has been reported to be 
three-fold (OR 2.92, 95% CI 1.44–5.95) among those aged 85 years and 
older compared to those aged 65–74 years (34). Using the same 
definition of polypharmacy and the same age class as reference group, 
a British study reported a 35% (95% CI 21–51%) increased risk for 
polypharmacy for those aged 75 years and older after controlling for 
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sex and living condition (55). In a population-based study of Finnish 
adults, an increase of 10 years in age was found to be associated with a 
35% increased risk of polypharmacy (89).  
There are also some studies reporting a weakening association or 
no association for polypharmacy with ageing (49,138,146,158). It seems 
that the importance of age as a predictor of polypharmacy diminishes 
in institutional and hospital settings. This is argued by studies 
showing the association between polypharmacy and age to be 
statistically non-significant in Medicaid recipients (138), during 
hospital stays (49) and at discharge from acute care hospital (146).  
 
Residential status 
It is apparent that polypharmacy is related to living in institution, as 
elderly persons needing assistance in their living are generally in 
poorer shape and suffer from more diseases than those living at home. 
A recent Swedish study reported that institutionalized elderly persons 
aged 77 years and older had a significantly higher drug intake (mean 
6.3, 95% CI 5.4–7.2) than community-living elderly persons (mean 4.0, 
95% CI 3.8–4.3) (105). Several other studies have also reported that 
placement outside home predicts a higher number of drugs in use 
(75,79,118).  
After adjusting for age and sex, living in an institution was a very 
strong factor associated with polypharmacy (five or more drugs) (OR 
2.66, 95% CI 2.04–3.46) among elderly British persons aged 65 years 
and older (55). After more extensive controlling, a Swedish 
population-based study found an over three-fold risk of polypharmacy 
(five or more drugs) for those living in institution compared with 
community-living elderly persons (OR 3.44, 95% CI 2.23–4.55) (105). 
 
Socioeconomic position 
The socioeconomic position (SEP) in society of an individual is 
commonly determined based on income, education and occupation 
(166). The association between these three determinants of SEP and 
polypharmacy is poorly studied in elderly populations, and those few 
studies that have been published have shown rather inconsistent 
results (167). Recent Swedish studies have reported low education to 
be associated with increased probability of polypharmacy (five or 
32 
 
 
 
more drugs in use) (44,105). Of these, the population-based study 
reported low education (8 years or less) to correlate statistically 
significantly with polypharmacy (OR 1.46, 95% CI 1.02–2.07) after 
controlling for age and sex; however, this association did not remain 
significant when adjusted additionally for comorbidity, marital status 
and living situation (105). Similarly, unadjusted analysis of an elderly 
US population showed that low education (less than high school) was 
statistically associated with taking a greater number of prescription 
drugs, but the correlation was no longer significant after adjustments 
(33). The other register-based Swedish study reported low education to 
be associated with an 11% (95% CI 10–12%) increased probability of 
polypharmacy (five or more drugs) and a 15% (95% CI 13–17%) 
increased probability of excessive polypharmacy (ten or more drugs) 
after controlling for age, sex, comorbidity and type of residential area 
(44).  Besides these reported associations, there are also a couple of 
studies showing no association between a high number of drugs in use 
and educational level (55,62,144).  
Research on income and occupation as determinants of 
polypharmacy is limited. Both of these associations were analysed in 
the previously mentioned Swedish study showing no significant 
association with polypharmacy (105). An Irish study using solely 
income as a surrogate for socioeconomic status showed a statistically 
higher prevalence for the use of five or more drugs among relatively 
deprived compared to relatively affluent elderly persons (38). Other 
findings suggest that low total household monthly income (less than 
240 USD per month) is independently associated with a higher number 
of over-the-counter drugs used by elderly residents of a small town 
located in Brazil (168). An Italian study reported that economic status 
did not correlate with the overall number of drugs taken (52). 
Similarly, income was not associated with either the number of 
prescription drugs or the number of OTC drugs in a study of US 
community-dwelling elderly women (63).  
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4.2 HEALTH-RELATED FACTORS 
Self-reported health status  
Based on the longitudinal Zutphen Elderly Study, the proportion of 
elderly men rating themselves as healthy decreased from 50% to 35% 
over a period of five years (171). The pattern of worsening health over 
time has also been reported for elderly Swedish persons aged 77 years 
and older (172). Elderly persons reporting poor health status are more 
likely to be users of prescription drugs than those with better health 
status (76,93). The association between increasing number of 
prescription drugs in use and poorer self-reported health was reported 
in a Finnish cohort study (51). A study performed among Danish men 
revealed that every third (31%) elderly man using five or more 
prescription drugs reported their health as poor or fairly poor (173). 
Using the same definition of polypharmacy, a somewhat higher 
proportion (42%) was found for men living in South Wales (65). The 
association between polypharmacy and health status has also been 
reported in a Finnish study, in which 31% of those using six or more 
drugs concomitantly reported poor health status compared with 10% 
of those using fewer drugs (80). Based on a Swedish population-based 
study, poor self-reported health status is associated with a three-fold 
risk of receiving polypharmacy (five or more drugs) (OR 3.1, 95% CI 
1.82–5.17) in elderly persons aged 65-75 years after adjustments (62). 
For Germans aged 70 years and older, the rate of risk was about the 
same size (OR 2.80, 95% CI 1.52–5.13) (61).   
 
Morbidity 
As expected, several studies have shown multimorbidity to be 
associated with an increasing number of drugs in use 
(34,46,107,108,144,163,164). For those having three or more diagnoses 
the probability of high-level polypharmacy (ten or more drugs) during 
hospital stay was significantly higher than for those having fewer 
diagnoses (49). A significant independent association was also 
reported between polypharmacy (five or more drugs) and four or 
more diseases (OR 3.44, 95% CI 2.05–5.75) (48). Based on the Women’s 
Health Study, there is an 8% (95% CI 3%–13%) increase in total number 
of drugs in use for each additional disease (63). 
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Of specific disease states, diabetes is one of the strongest factors 
associated with polypharmacy. All of these studies have shown an 
over two-fold risk of polypharmacy (five/six or more drugs) for elderly 
persons having diabetes compared to those without diabetes 
(48,62,89,146,169). Different kinds of CVDs are also strong correlates of 
polypharmacy. Evidence is available especially on heart failure 
(66,89,146,170), coronary heart disease (66,89,142) and hypertension 
(61,62,65,66,89,107,170) as significant factors of increasing number of 
drugs in use. Other reported correlates of polypharmacy are 
respiratory diseases (61,89,146,170), pain (64,89), depression (48,146) 
and other psychiatric diseases (64,89).  
 
Nutritional status 
Nutritional status is of great concern particularly in elderly persons 
with polypharmacy due to its impact on the pharmacology of many 
drugs (188). Conversely, drugs may also adversely affect nutrition, as 
some drugs cause nausea and loss of appetite as a side effect (188,189). 
In addition, the occurrence of malnutrition is promoted by problems in 
chewing and swallowing as well as the overall reduction in appetite 
that occurs as people age (190,191). Recent studies examining the 
nutritional state of elderly persons by Mini Nutritional Assessment 
(MNA) test have reported high prevalences for malnutrition (9–36%) 
and risk of it (37–51%) (192-196). In Belgium, malnutrition was 
observed in every third (33%) and risk of malnutrition in two-fifths 
(43%) of elderly hospital patients (197). Finnish studies using the MNA 
test in screening indicate that almost all (89%) residents in nursing 
homes (198) and half (53%) of persons receiving home care (199) are 
malnourished or at risk of it.  
So far, very little research has been conducted on the association 
between polypharmacy and nutritional status in elderly cohorts. A US 
study indicated a statistically significant negative correlation between 
the number of drugs taken and MNA scores (200). However, these 
results need to be interpreted with caution because of the small (n=81) 
study group. Support for these results is presented in some studies 
showing polypharmacy to be associated with weight loss and BMI as 
determinants of nutritional status (58,62,65). A study conducted in 
community-dwelling settings revealed an increased likelihood of 
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experiencing weight loss (10 or more pounds) among those using 3–4 
drugs (OR 1.96, 95% CI 1.08–3.54) and those using 5 or more drugs 
(OR 2.78, 95% CI 1.38–5.60) after adjustments for age, sensory 
impairments, medical comorbidities, hospitalizations, cognitive 
impairments and depressive symptoms (58). In a Swedish study, 
obesity (BMI 30.0 or more) was shown to be associated with 
polypharmacy (five or more drugs in use) (OR 2.3, 95% CI 1.32–3.92) 
(62). Increasing BMI scores with the number of prescription drugs in 
use has also been observed among English men (65). Based on these 
results it can be suggested that drugs themselves may contribute to 
changes in weight, even beyond the diseases; however, this association 
needs to be confirmed by further investigation. 
 
Functional ability 
Old age is a major factor contributing to increased occurrence of 
functional disabilities (171). With regard to the association between 
functional ability and drug use, elderly persons having impairments in 
physical function have higher prevalences of prescription drug use 
than those without functional limitations (p<0.05) (93). Polypharmacy 
(five or more drugs) was also independently associated with impaired 
balance (OR 1.80, 95% CI 1.02–3.19) in elderly German persons aged 72 
years and older (58). Of specific drug groups, anticholinergic and 
sedative medication are most commonly associated with poor physical 
performance (201).  
Studies concerning the association of functional ability with 
polypharmacy have mainly used basic Activities of the Daily Living 
(ADL) screening test as a measure of current functional status. One of 
these reported no association between low function (scores of 11 or 
less) and the use of six or more prescription drugs (142), whereas 
another study conducted in a nursing home setting found that 
residents needing assistance in all measured five ADLs had a lower 
risk of receiving nine or more drugs than did those receiving 
assistance with four or less ADLs (108).  
The findings on the association of Instrumental Activities of Daily 
Living (IADL) scores with polypharmacy are contradictory. In a cross-
sectional study of elderly German persons, dependency on IADL was 
found to be an independent factor associated with polypharmacy (five 
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or more drugs in regular use) after adjusting for age and sex (OR 1.91, 
95% CI 1.03–3.56) (61).  On the contrary, a study from Italy found no 
statistically significant association between dependency in at least one 
activity of IADL and use of seven or more prescribed drugs (OR 1.19, 
95% CI 0.93–1.52) (146). The difference in results of these two studies 
may, at least partly, be explained by different study populations; the 
first study included primary care patients and the second patients 
discharged to geriatric or internal wards. In addition, the Italian study 
adjusted more widely potential confounders than the German study. 
An interesting correlation between the need of assistance with at least 
one IADL and underuse of drugs, but not polypharmacy, was reported 
among US veterans (153).  
There are also some studies that have reported functional status to 
be a correlate of polypharmacy without using any specific screening 
test in measuring current functional state. In elderly persons living in 
Hong Kong, dependency in daily activities was reported to correlate 
with polypharmacy (five or more drugs in use), but after adjustments 
this association did not remain significant (48). Among elderly 
Taiwanese persons, on the other hand, poor physical functioning was 
significantly associated with polypharmacy (five or more prescription 
drugs), even after adjustments for several sociodemographic and other 
variables reflecting the overall health status (46).  
 
Cognitive capacity 
It is well known that age is associated with a progressive loss of 
cognitive capacity, seen as increasing prevalence of dementia with 
ageing (202-204). According to the EUROCODE report, the prevalence 
of dementia among persons aged 65 years and older varies between 
6% and 10% in Europe (205). Among Finnish home-dwelling elderly 
persons aged 75 years and older the prevalence was 15% at the end of 
the 1990s (206). An equal prevalence (14%) was observed among US 
elderly persons aged 71 years and older (202).  
Polypharmacy (five or more drugs) is more prevalent among 
elderly persons with dementia (55%) than those without dementia 
(33%) (47). Conversely, a US study reported cognitive impairments to 
be associated with reduced prescription drug use (63). In addition, 
some studies have shown specific drug categories, most commonly 
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anticholinergics and sedative drugs, to be associated with poorer 
cognitive performance (207-210). However, prior studies concerning 
the direct association between polypharmacy and cognitive capacity 
cannot be found. In conclusion, the lack of evidence suggests that 
further research should be done on the role of drug treatment, 
especially specific drug categories and polypharmacy, in cognitive 
performance.  
4.3 USE OF HEALTH SERVICES AND PATIENT ADHERENCE 
Use of health services 
A declined overall health status and increased occurrence of diseases 
with ageing make elderly persons big consumers of health services. 
Some studies have shown the number of prescribers to correlate 
positively with the number of drugs in use (53,111,138). Additionally, 
an increased number of visits to physicians is associated with 
polypharmacy (33,34,95). In a cohort of Swedish nursing home 
residents, the number of drugs was positively associated with the 
number of prescribers (111). A similar association was found with the 
tendency for visiting multiple providers in a large population-sample 
of Taiwanese persons aged 85 years and older (46). According to a US 
study, the prevalence of office-based visits to physician by elderly 
persons with polypharmacy increased from 7% to 19% between the 
years 1990 and 2000 (163). Concerning specialist visits, the average 
number of these visits over a three-year period has been reported to be 
higher among those using ten or more drugs (3.80 visits) compared 
with those using no drugs or one drug (0.21 visits) (139). When 
examining the association between polypharmacy and prescribing 
patterns, substantial variation occurs in the prevalence of 
polypharmacy between practices that can partly be explained by 
practice-related factors, such as practice structure, workload and 
clinical work profile (174). 
An Austrian study reported a significant correlation between the 
need of nursing care and the use of seven or more prescription drugs 
continuously (107). In a Finnish study, a statistically significant 
difference in the prevalence of the use of home nursing services was 
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reported between those using six or more drugs (13%) and those using 
fewer drugs (4%) (80). An increasing number of drugs in use is also a 
significant predictor of hospitalizations (33,139). A Dutch study 
reported polypharmacy to be a significant determinant of preventable 
medication-related hospital admissions (OR 2.7, 95% CI 1.6–4.4) (175). 
There is also evidence on increased risk of hospital admission because 
of an adverse reaction with the number of drugs in use (176,177). The 
association of polypharmacy with length of hospital stay has also been 
shown:  staying in an Indian hospital for ten or more days was 
associated with the use of ten or more prescription drugs (49), while 
staying in US nursing homes for 3–6 months is associated with the use 
of nine or more prescription drugs (108).  
 
Adherence to drug treatment 
High rates of medication non-adherence have been common findings 
in studies examining drug use patterns of elderly persons (162,178-180), 
but the association between adherence and the number of drugs in use 
is poorly reported. There are some studies reporting significant 
positive correlation between non-adherence and the number of drugs 
in use (181-183). Among home health care patients using three or more 
drugs continuously, underuse (at least one drug with <70% adherence) 
was observed in every third (31%) and overuse (at least one drug >130% 
adherence) in every fifth (18%) based on pill counts (98). According to 
a US study, in every fifth (17%) elderly person the number of drugs in 
use was observed as a factor interfering with their ability to use drugs 
as prescribed (184). A remarkably higher (54%) prevalence for non-
adherence was found for Australian nursing home residents (185). A 
Spanish study reported that over two-fifths (44%) of elderly persons 
using five or more drugs are non-adherent with their medication (186). 
A study of elderly Danish persons showed an over two-fold risk (OR 
2.5, 95% 1.5–4.1) for non-adherence among those using three or more 
drugs compared with those using fewer drugs (183). Finnish studies 
have reported deviations from medication (e.g. dose, frequency) to 
correlate positively with the number of prescription drugs in use 
(128,149). Furthermore, disagreement between doctor and an elderly 
patient over the number of drugs taken was a significant factor 
associated with polypharmacy (five or more drugs) (61). In a US study, 
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a high number of drugs in use also correlated with a higher risk of 
hospitalization due to non-adherence (130). For elderly persons using 
five or more drugs, an association between non-adherence and 
mortality has been shown (OR 2.87, 95% CI 1.80–2.57) (186).  
Studies have explained high rates of non-adherence among those 
with polypharmacy by intentional non-adherence, meaning that 
elderly persons deliberately choose not to adhere with medication in 
order to avoid adverse drug effects. It is also possible that non-
adherence occurs partly due to overprescribing, argued by studies 
reporting drug use without clear indication to be common among 
elderly persons (11,39) and associated with polypharmacy (66). It can 
be concluded that the phenomenon of non-adherence among elderly 
persons with polypharmacy is poorly understood, calling for the need 
of research on this topic.  
4.4 MORTALITY 
Elderly persons with polypharmacy typically suffer from several long-
term diseases that lead to increased risk of death. The incidence of 
deaths in polypharmacy patients over a one-year period was 
determined among residents of Veterans Affair Centre, showing ten 
times higher death rates for those using ten or more drugs compared 
to typical population of this residence (1.77 deaths per 100 patient-
months vs. 0.18 deaths per 100 patient-months) (211). Previous studies 
on the association of drug use with mortality have mostly focused on 
analysing the role of inappropriate drug use in mortality of elderly 
persons (59,212). Some studies have shown polypharmacy to be 
associated with a high frequency of fatal adverse drug events 
(213,214).  However, these studies did not determine whether a high 
number of drugs in use was an independent risk factors for all-cause 
mortality.  
It is obvious that increasing morbidity with age is the main factor 
causing deaths, making it difficult to show the role of polypharmacy as 
an independent factor associated with death. This may be the reason 
why the relationship between polypharmacy and mortality has 
scarcely been analysed, as there are only a couple of studies reporting 
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weak associations with mortality (120,215,216). The impact of 
polypharmacy on mortality was evaluated in a US study conducted in 
general population of aged 65 years and older (216). This study found 
that participants using more than four drugs had an approximately 
30% increased risk of 8-year mortality compared to those using four or 
fewer drugs, after adjustment for several sociodemographic factors, 
common diseases, self-reported health status and functional 
limitations. However, this contribution of polypharmacy to mortality 
should be interpreted with caution, because this adjusted association 
remained barely statistically significant (OR 1.27, 95% CI 1.04–1.56). In 
a Japanese study of hospitalized persons aged 85 years and older, the 
one-year post-discharge mortality for those using six or more drugs 
was over three-fold compared with those using two or fewer drugs 
(120). The variables adjusted for included demographics, use of drugs 
within specific drug category, Charlson co-morbidity index and other 
variables indicating the current health status of participants. Another 
study conducted in a hospital setting included Spanish elderly patients 
admitted to an acute geriatric ward (215). In this study, the risk of 
hospital mortality was shown to be over two-fold for those with 
polypharmacy compared to those without polypharmacy both at 
discharge (OR 2.22, 95% CI 1.52–3.24) and six months after hospital 
discharge (OR 2.20, 95% CI 1.62–3.00).  
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5  Summary of the 
Literature  
The literature review of this thesis concentrated on describing the 
changes occurring in overall drug use in elderly persons since the late 
1960s. As expected, convincing evidence was found of a change in 
most common types of drugs and an increase in the quantity of drug 
use and prevalence of polypharmacy. However, the review of 
literature revealed that studies examining the overall drug use were 
published mainly in the 1980s and 1990s. After that research has 
concentrated on correlates of polypharmacy instead of describing the 
overall drug use. Thus, there is a clear need for research describing the 
current situation of drug use in elderly persons. In addition, although 
several studies have shown that the number of drugs used by elderly 
persons has been growing in the course of time, only a few 
longitudinal follow-up studies have been carried out on the changes in 
drug use over time and with ageing.  
Based on the literature review, several sociodemographic factors 
have been associated with polypharmacy. The evidence on diseases 
and other health-related factors and mortality as correlates of 
polypharmacy is scarce. As expected, multimorbidity is a strong 
correlate of polypharmacy; however, the research on the role of 
specific diseases for polypharmacy is mainly lacking. With regard to 
other health-related factors, it was observed that only little attention 
has been paid to their role in polypharmacy. In addition, previous 
studies have reported associations only with polypharmacy, without 
separating polypharmacy and excessive polypharmacy.  
 
Overall drug use and polypharmacy  
The literature review revealed that cardiovascular drugs have 
remained the most commonly used group of drugs over the past 
decades; however, new drug launches for the treatment of various 
heart conditions have changed the variety of the most commonly used 
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pharmacological substances. Over a period from the 1970s to the 2000s, 
an increase is also observable in the use of drugs for blood and blood 
forming organs and drugs for the nervous system. It seems that these 
observations can mainly be explained by the adoption of 
antithrombotic drugs as part of the treatment pattern and the 
increasing use of hypnotics, sedatives and anxiolytics. In addition, the 
use of analgesics and antipyretics showed increased frequencies 
during the 1990s and 2000s, while the estimates for the use of drugs for 
the alimentary tract and metabolism (including mainly GI drugs, 
vitamins, mineral supplements and drugs for diabetes mellitus) have 
shown no remarkable change in frequency since the 1970s until now. 
These conclusions are mainly based on the comparisons of separate 
cross-sectional studies. More reliable information on the changes 
occurring in the types of drug used over time and with ageing could 
be offered by longitudinal cohort studies, but such studies are scarce. 
Due to different populations and inconsistent definitions for drug 
use in studies taken into account in this literature review, direct 
conclusions on the quantity of drug use and the prevalence of 
polypharmacy are somewhat problematic calling for more longitudinal 
studies on changes occurring in drug use. However, studies reporting 
the quantity of drugs showed that the mean number of drugs used has 
increased remarkably over time. In Nordic population-based studies 
conducted during the 1970s and 1980s, the reported means were 
mainly between three and four drugs, including prescription and over-
the-counter drugs. Thereafter, during the 1990s and 2000s, means 
between four and five drugs have generally been observed. Similar 
numbers were also found in other studies of population-based samples 
and community-dwelling elderly persons, but the range between 
different countries was wide. Predictably, review of previous studies 
showed that elderly hospital patients and nursing home residents are 
on average using a remarkably higher number of drugs compared to 
community-dwelling elderly persons. In general, the highest means 
were seen in US studies and the lowest in European studies, excluding 
the Nordic countries.  
With regard to polypharmacy, generalizing roughly, it can be 
concluded that approximately every fifth elderly person was using five 
or more drugs in studies of population-based samples and 
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community-dwelling elderly persons conducted during the 1970s and 
1980s. After that, a remarkable increase was observable in prevalences, 
as polypharmacy was observed in about two-fifths of the elderly in the 
1990s and in about one half in the 2000s. Estimates for excessive 
polypharmacy have been reported during the past two decades, 
showing about every fifth elderly person to use nine/ten or more drugs 
concomitantly. Prevalence estimates for elderly hospital patients and 
nursing home residents have been reported since the 1990s, showing 
polypharmacy in more than half of them fairly consistently. 
Differences in prevalences for polypharmacy and excessive 
polypharmacy between countries were similar to previously 
mentioned variation in the quantity of drug use.  
 
Factors associated with polypharmacy 
This literature review describes both factors that influence 
polypharmacy and outcomes that are influenced by polypharmacy. 
For some factors it is not clear whether they represent determinants or 
consequences of polypharmacy.  Evidence of female sex and advanced 
age as correlates of polypharmacy is strong. Based on studies 
presenting age-specific analyses on drug use, it seems that the 
consumption of drugs increases up to 90 years of age, after which it 
begins to decrease. It has also been shown that for those living in 
institutions the risk for polypharmacy and excessive polypharmacy is 
multifold compared to those living in their own home. Of 
socioeconomic factors, low education has been reported to associate 
with polypharmacy, while the results of associations of polypharmacy 
with other surrogates of socioeconomic factors (income, occupation) 
are controversial.  
 Available evidence on health-related correlates of polypharmacy is 
much scantier compared to sociodemograpchic factors. As expected, 
multimorbidity has been shown to correlate strongly with increased 
occurrence of polypharmacy. Of specific diseases and symptoms, an 
association with polypharmacy has been found for different kinds of 
CVDs, diabetes, respiratory diseases, pain, depression and other 
psychiatric diseases. However, in the light of previous literature the 
role of specific diseases has been fairly poorly studied. There are also 
few studies on a positive correlation between polypharmacy and the 
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use of health services, including the number of visits to physician, 
need of nursing care, hospital admissions and length of hospital stays. 
The elderly themselves also have a crucial role in implementing 
prescribed medication, despite the fact that the association between 
adherence and polypharmacy is poorly reported, as only a few studies 
have reported a correlation between a high number of drugs in use 
and non-adherence for elderly populations.  
According to some previous studies, elderly persons reporting 
declined overall health have increased probability for polypharmacy. 
Commonly used markers of health among the elderly are nutritional 
status, functional ability and cognitive capacity, whose relationship 
with polypharmacy has been poorly studied. There are only a few 
studies reporting that a high number of drugs in use is associated with 
different determinants of a declined nutritional status, including 
lowered MNA scores, weight loss and decreased BMI. The findings on 
the association of polypharmacy with declined functional ability are 
contradictory; however, most studies report need of assistance in 
ADL/IADL to be a significant correlate of polypharmacy. Among 
demented patients, the prevalence of polypharmacy was found to be 
high. However, prior studies concerning the direct association 
between polypharmacy and cognitive capacity cannot be found.  
Previous studies on the association of drug use with mortality have 
mostly focused on analysing the role of inappropriate drug use in 
mortality of elderly persons. The relationship between polypharmacy 
and mortality has scarcely been analysed, as there are only a couple of 
studies reporting weak associations with mortality. An independent 
role of polypharmacy in mortality is difficult to show, as it is obvious 
that increasing morbidity with age is the main factor causing deaths in 
elderly persons.  
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6 Aims of the Study  
The general aim of this study was to descibe the changes occurring in 
overall drug use and polypharmacy over time and with ageing in 
elderly Finnish population aged 75 years and older. In addition, the 
study aimed at evaluating the role of demographics, diseases and 
other health-related determinants as factors associated with 
polypharmacy. 
 
More specifically, the aims addressed in this study were: 
 
1. To describe the changes in types of drugs used, quantity of 
drug use and polypharmacy over time and with ageing 
 
2. To evaluate demographic and health-related factors as 
relevant correlates of polypharmacy, with special reference to 
the number and type of medical diagnoses and symptoms  
 
3. To determine the association of polypharmacy with nutritional 
status, functional ability and cognitive capacity 
 
4. To evaluate the indicative value of polypharmacy status to 
mortality  
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7 Materials and Methods  
The data used in this thesis are derived from two separate population-
based cohort studies, the Kuopio 75+ Study and the GeMS Study 
(Table 4). Both of these longitudinal studies were conducted in the city 
of Kuopio, Finland, for a population of aged 75 years and older. The 
Kuopio 75+ Study gave background information on overall health 
status, current medication and service use of elderly participants. The 
results of the Kuopio 75+ Study showed the need of intervention study 
to improve the treatment of elderly persons.  Thus, the study plans of 
the GeMS intervention study were done. Because of similarly defined 
study populations, there was a possibility that one person has taken 
part in both studies. There is no available information on exact 
numbers of these persons. However, it hardly has any influence on the 
results because the Kuopio 75+ Study did not include any 
interventions. 
 
Table 4. Summary of study designs, data materials and main outcomes of interest in 
works included in this thesis 
Article Design Data 
source 
Study period 
& population 
Outcome of 
interest 
Work I Cohort Kuopio 75+ 1998–2003 
n=339 
Drug use and 
polypharmacy 
 
Work II Cross-
sectional 
Kuopio 75+ 1998 
n=523 
Correlates of 
polypharmacy,  
relation between 
drugs and diagnoses 
 
Work III Cohort GeMS1 2004–2007 
n=294 
Association of 
polypharmacy with 
nutritional status, 
functional ability and 
cognitive capacity 
 
Work IV Cohort Kuopio 75+ Phase I:  
1998-2002 
n=601 
Phase II: 
2003–2007 
n=339 
Relation  
between 
polypharmacy  
and mortality 
 
1Geriatric Multidisciplinary Strategy for the Good Care of the Elderly 
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7.1 KUOPIO 75+ STUDY 
The Kuopio 75+ Study is a multidisciplinary prospective health survey 
on the clinical epidemiology of diseases, current drug use and 
functional capacity in elderly persons. This dataset was used in three 
publications of this thesis (Works I, II and IV).  
7.1.1 Study population 
All inhabitants of the city of Kuopio, Finland, born before 1 January 
1923 (n=4 518), i.e. those aged 75 years and older in 1998 (Figure 2) 
were eligible for the Kuopio 75+ Study. The study cohort was formed 
by drawing a random sample of 700 elderly persons from this 
population on 1 January 1998. Of this sample, 15 persons died before 
the examination, and 84 persons refused to participate or could not be 
contacted. During 1998 the remaining 601 persons took part in the 
baseline examination, yielding a participation rate of 86%. The follow-
up examination in 2003 was carried out on 339 survivors (Figure 3). 
The loss of participants during the five-year follow-up was significant 
due to numerous deaths (n=233). In addition, 29 participants refused to 
participate in the follow-up examination or could not be contacted.  
 
Work I 
The population of this article comprised survivors (n=339) who were 
examined both at baseline in 1998 and at follow-up in 2003. The 
majority of them were women (75%) (Table 5). Of this population, 4% 
(n=13) were in institutional care at baseline.  
 
Work II 
In this cross-sectional article, only participants living at home in 1998 
(n=523) were included (Table 5).  A total of 73% of them were women, 
and 48% were aged less than 80 years.   
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Figure 2. Flow chart of the population-based Kuopio 75+ Study conducted in 1998 and 
2003 
  
Random Sample 
n=700 
Baseline in 1998 
n=601 
Follow-up in 2003 
n=339 
Target population  
Aged 75 years in the city of 
Kuopio on 1 January 1998 
n=4,518 
Loss between 1998 and 2003  
n=262 
(n=233 died, n=29 refused or  
could not be contacted) 
Non-participants  
n=99 
(n=15 died, n=84 refused 
or could not be contacted) 
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Table 5. Main characteristics of study populations from the Kuopio 75+ Study 
database used in three works of this thesis 
 
 Work I Work II Work IV 
 
Characteristic 
 
n=339 
 
n=523 
Phase I 
n=601 
Phase II 
n=339 
Baseline study 
year 
1998 1998 1998 2003 
Age, mean  
        (range) 
80.2  
(75.3–94.5) 
81.2  
(75.2–95.9) 
81.6  
(75.2–96.8) 
84.9  
(80.2–99.3) 
Age group, n (%)     
   75–79 years 191 (56) 250 (48) 266 (44) – 
   80–84 years 98 (29) 157 (30) 183 (31) 194 (57) 
   85+ years 50 (15) 116 (22) 152 (25) 145 (43) 
Sex, n (%)     
   Men 85 (25) 143 (27) 156 (26) 85 (25) 
   Women 254 (75) 380 (73) 445 (74) 254 (75) 
Residential  
status, n (%) 
    
   Home 326 (96) 523 (100) 523 (87) 289 (85) 
   Institution 13 (4) – 78 (13) 50 (15) 
Self-reported  
health status, n (%) 
   
   Good  122 (37) 185 (36) 196 (35) 147 (48) 
   Moderate 162 (49) 240 (47) 261 (46) 104 (35) 
   Poor 47 (14) 90 (17) 106 (19) 50 (17) 
   missing, n 8 8 38 38 
 
  
Work IV 
For the purpose of this article, the population was determined 
separately in two phases (Table 5). Analyses were made in two phases 
in order to control better inevitable changes that occur over time in 
polypharmacy groups at individual level. In the first phase, the 
population was made up of 601 participants aged 75 years and older 
examined at baseline in 1998. Their survival was monitored from 1998 
to 2002. In the second phase, the survivors examined in 2003 (n=339, 
aged 80 years and older) were included. Their survival was monitored 
from 2003 to 2007.  
In both phases three out of four participants were women (Table 5).  
The mean age was 81.6 years (range 75.2–96.8) in the first phase and 
84.9 years (range 80.2–99.3) in the second phase. The proportion of 
home-living participants was about the same in both phases.  
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7.1.2 Data collection 
The participants underwent a structured clinical examination and 
interview at baseline in 1998. These assessments were mainly 
conducted in the outpatient clinic of the municipal hospital. Those 
who could not come to clinic were examined at home. If participants 
were unable to answer the questions, the required information was 
given by a close relative or a caregiver.   
During the interview, a trained nurse interviewed the participants 
and recorded the drugs that the participants were currently taking 
regularly or as needed, based on the drug containers and prescriptions 
the participants were asked to bring with them (Appendix 1). 
Vitamins, mineral supplements and herbal products were also 
documented. Furthermore, a geriatrician examined the participants 
and diagnosed their current diseases. To gain a comprehensive history, 
the geriatrician reviewed the participants’ medical records thoroughly. 
The reliability of reported former and current diagnoses was improved 
by using primary and secondary care records to complement long-
term information about the participants’ health status. Medical records 
were available from Kuopio University Hospital, municipal hospitals, 
local hospitals and home nursing services. As part of the study 
protocol, information on the participants’ sociodemographic 
background, living condition, social contacts, health behaviour and 
health status was also recorded. The follow-up examinations 
conducted in 2003 used the same set of procedures as at the baseline 
assessment, except that there was no clinical examination by a 
geriatrician.   
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7.2 GERIATRIC MULTIDISCIPLINARY STRATEGY FOR THE 
GOOD CARE OF THE ELDERLY STUDY (GEMS) 
The population-based GeMS Study was designed to develop a model 
of geriatric assessment, care and rehabilitation suited for primary 
health care needs. One publication (Work III) of this thesis is based on 
the data from the GeMS Study.  
7.2.1 Study population 
The target population of the GeMS study was defined on 1 November 
2003, as inhabitants aged 75 years and older living in the city of 
Kuopio, Finland (Figure 3). The study sample comprised 1000 
randomly selected persons from this population. These participants 
were randomly divided into two same-sized (n=500) groups: 
intervention and control groups.  
The study protocol included yearly examinations during a three-
year period from 2004 to 2007 for both intervention and control 
groups. The baseline examinations in 2004 were performed on 377 
control group (participation rate 75%) and 404 intervention group 
(participation rate 81%) participants (Figure 3). The loss during the 
follow-up was mainly due to deaths, but also refusals occurred to 
some extent in both groups. In the publication (Work III) of this thesis, 
study population comprised of the control group participants in 2004. 
The control group was chosen in order to reflect the overall situation 
without bias of interventions over time. Concerning the unpublished 
results, the baseline population (n=781) could be done as a whole 
because baseline protocol was similar to both intervention and control 
groups. Interventions started after the baseline examinations. The 
intervention group is described in detail elsewhere (217). 
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Figure 3. Flow chart of the control group participants aged 75 years and older in the 
population-based GeMS Study conducted yearly from 2004 to 2007 
 
 
 
Control group  
n=500 
Baseline in 2004  
n=377 
First follow-up in 2005 
n=346 
Third follow-up in 2007  
n=294 
Non-participants  
n=38 died, n=85 refused 
Target population  
Aged ≥75 years in the city of 
Kuopio on November 1, 2003 
n=5,615 (January 1, 2004) 
Random sample  
n=1000 
Loss between 2005 and 2006  
n=25 died, n=2 refused,  
n=1 migrated from the region 
Second follow-up in 2006 
n=318 
Loss between 2006 and 2007  
n=22 died, n=2 refused 
Loss between 2004 and 2005  
n=25 died, n=5 refused, 
n=1 could not be contacted 
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Work III 
The population of this publication was comprised of control group 
participants. The loss during the three-year follow-up until 2007 was 
mostly due to deaths (Figure 3). Most of the refusals (n=85) were 
obtained before the first examination. At the end of the follow-up, the 
size of the control group was 294 participants. In the study cohort, 
seven out of ten survivors were women (Table 6). At baseline in 2004, 
the vast majority (95%) of participants were home-dwelling.  
  
Table 6. Main characteristics of study population at baseline in 2004 from the GeMS 
Study database used in one work of this thesis  
 
 Work III 
Characteristic n=294 
Baseline study year 2004 
Age, mean  
        (range) 
81.3  
(75.6–98.4) 
Age group, n (%)  
   75–79 years 142 (48) 
   80–84 years 91 (31) 
   85+ years 61 (21) 
Sex, n (%)  
   Men 91 (31) 
   Women 203 (69) 
Residential status, n (%)  
   Home 278 (95) 
   Institution 16 (5) 
Self-reported health status, n (%)  
   Good 131 (45) 
   Moderate 125 (43) 
   Poor 35 (12) 
   missing, n 3 
 
7.2.2 Data collection 
The data on control group participants of GeMS Study were obtained 
from structured interviews carried out yearly by a trained nurse at the 
outpatient clinic. Institutionalized participants were interviewed in 
their current residence. The collected data included information on 
sociodemographic characteristics, overall health status, current 
medication and the use of health and social services. If participants 
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were unable to answer the questions, the required information was 
provided by a close relative or a caregiver. 
Current medication was recorded during the interview on the basis 
of prescriptions and drug containers that the participants were asked 
to bring with them (Appendix 2). The reliability of data on drug use 
was increased by checking the medical records available from primary 
and specialized health care. Screening tests for nutritional status, 
functional ability and cognitive capacity were completed by nurses as 
part of the study protocol.  
7.3 COMPARISONS BETWEEN THE KUOPIO 75+ STUDY AND 
THE GEMS STUDY 
Changes in drug use patterns and polypharmacy over time and with 
ageing were examined in two different settings. Firstly, the changes 
were described in separate cohorts of persons aged 75 years and older 
in 1998 and 2004. Secondly, longitudinal changes in drug use were 
reported for elderly persons aged 75 years and older at baseline during 
two different time periods: over a five-year period from 1998 to 2003 
(Kuopio 75+ Study) and over a three-year period from 2004 to 2007 
(GeMS Study).  
7.3.1 Cohorts of persons aged 75 years and older  
Comparisons between two age cohorts were done using data from 
both the Kuopio 75+ Study and the GeMS Study. The first age cohort 
comprised participants who took part in the Kuopio 75+ Study in 1998 
(n=601) (Figure 2). The second age cohort included the GeMS Study 
participants examined in 2004 (n=781) (Figure 3). At both cross-
sectional time points, the participants were 75 years and older.  
 Comparison of main characteristics did not reveal differences 
between the two cohorts (Table 7). In both studies, three quarters of 
the participants were women, and nine out of ten were living at home.  
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Table 7. Main characteristics for age cohort 75 years and older in the Kuopio 75+ 
Study in 1998 and the GeMS Study in 2004 
 
 
 
Characteristic 
Kuopio 75+ Study 
1998 
n=601 
GeMS Study 
2004 
n=781 
Age, mean (SD) 81.7 (4.6) 81.7 (5.0) 
Age group, n (%)   
   75–79 235 (39) 362 (46) 
   80–84 198 (33) 241 (31) 
   85+ 168 (28) 178 (23) 
Sex, n (%)   
   Male 156 (26) 233 (30) 
   Female 445 (74) 548 (70) 
Residential status, n (%)   
   Home 523 (87) 700 (90) 
   Institution 78 (13) 81 (10) 
Self-reported health status, n (%) 
   Good 196 (35) 327 (43) 
   Moderate 261 (46) 311 (41) 
   Poor 106 (19) 118 (16) 
   missing, n 38 25 
 
7.3.2 Follow-up of survivors  
Changes in drug use patterns and polypharmacy with ageing were 
evaluated using two different cohorts. The first cohort included 339 
survivors from the Kuopio 75+ Study, and their drug use was 
evaluated over a five-year period from 1998 to 2003 (Figure 2). The 
second cohort comprised 294 survivors from the control group of the 
GeMS Study (Figure 3). Data used in the analysis of this thesis were 
collated over a three-year period from 2004 to 2007.  
The proportion of women was slightly higher in the Kuopio 75+ 
Study (75%) than in the GeMS Study (69%) (Table 8). During the 
follow-up of both cohorts, the proportion of those living in 
institutional care increased with ageing. An increase was also observed 
in the prevalence of poor self-reported health status.  
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Table 8. Main characteristics of survivors in the Kuopio 75+ Study from 1998 to 2003 
and the GeMS Study (control group) from 2004 to 2007  
 
 Kuopio 75+ Study GeMS Study 
 
Characteristic 
1998 
n=339 
2003 
n=339 
2004 
n=294 
2007 
n=294 
Age, mean (SD) 80.2 (3.9) 84.9 (3.8) 81.3 (4.5) 84.0 (4.6) 
Sex, n (%)     
   Male 85 (25) 85 (25) 91 (31) 91 (31) 
   Female 254 (75) 254 (75) 203 (69) 203 (69) 
Residential status, n (%) 
   Home 326 (96) 289 (85) 278 (95) 257 (87) 
   Institution 13 (4) 50 (15) 16 (5) 37 (13) 
Self-reported  
health status, n (%) 
   
 
   Good 122 (37) 147 (49) 132 (45) 114 (41) 
   Moderate 162 (49) 104 (34) 124 (43) 108 (39) 
   Poor 47 (14) 50 (17) 35 (12) 57 (20) 
   missing, n 8 38 3 15 
7.4 DEFINITIONS AND MEASURES 
The definitions for drug use and polypharmacy are similar in all 
publications of this thesis. The main outcome measures and other 
relevant measures were defined according to widely used and 
validated screening tests or commonly accepted ways.  
7.4.1 Drug use  
Drug use refers to consumption of drugs, vitamins and mineral 
supplements taken regularly and as needed. Herbal products were not 
taken into account because information on their use could not be 
collected consistently. Drugs taken daily or at regular intervals were 
defined as being in regular use, whereas drugs taken occasionally were 
defined as drugs taken as needed.  
Drugs were classified according to the Anatomical Therapeutic 
Chemical (ATC) classification system issued by the Nordic Council on 
Medicines (84). This classification system used commonly in drug 
utilization studies is published and updated yearly by the World 
Health Organization (WHO) collaborating centre in Oslo, Norway. The 
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latest available version of this classification was used in coding drugs 
in this study.  
7.4.2 Polypharmacy status  
For this analysis, the participants were divided into three groups 
according to the number of drugs in use. In this classification, 
excessive polypharmacy was defined as the use of ten or more drugs 
concomitantly; correspondingly, polypharmacy refers to the use of six 
to nine drugs. The non-polypharmacy group included persons using 
five or fewer drugs concomitantly.  
 These cut-off points were chosen based on previous studies and 
current treatment patterns of elderly populations. Although there is as 
yet no consensus or commonly used cut-off point for excessive 
polypharmacy, nine/ten or more drugs has been used to define 
excessive polypharmacy in recent studies (44,67,69,70,87,108). To 
define polypharmacy, earlier studies have mostly used five or more 
drugs (35,52,59,61,65,173) as a cut-off point, but four or more drugs 
(13,34) and six or more drugs (66,80,142) have also been used. 
Reflecting the expanding opportunities for drug treatment of the 
elderly, we chose a higher cut-off point for polypharmacy. The 
inclusion of non-prescription drugs, vitamins and mineral 
supplements in studies of this thesis justified this decision; in contrast, 
several other studies have taken into account only prescribed drugs 
(41,42,44,45,142). 
7.4.3 Main outcome measures 
In this thesis, the associations of polypharmacy with different 
outcomes were examined. The four main outcomes used were 
mortality, nutritional status, functional ability and cognitive capacity 
(Works III and IV).  
 
Ascertainment of mortality (Work IV) 
Mortality was assessed in two separate phases, as presented 
previously. In the first phase survival was defined as the time from the 
date of examination in 1998 until death or the end of the follow-up 
period on 31 December 2002. For surviving participants, the second 
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phase covered the time from the date of examination in 2003 until 
death or the end of the follow-up period on 31 December 2007.  
 The dates of death were derived from Statistics Finland, which is 
the official National Health Register Authority maintaining an archive 
of death certificates of Finnish population (218). The statistics on 
deaths are compiled annually using data from death certificates and 
supplement data from the Central Population Register. The data used 
concerning the dates of death are comprehensive because the death 
certificates are obligatory for all persons who are domiciled in Finland 
at their time of death. 
 
Assessment of nutritional status (Work III) 
Nutritional status was determined yearly using the Mini Nutritional 
Assessment (MNA) test, which is the most widely used nutritional tool 
with high sensitivity and validity for elderly population (219) 
(Appendix 3). A short version (MNA-SF) used in this study consists of 
six questions from the full MNA on different domains of nutritional 
well-being, including eating problems, weight loss, mobility, 
neuropsychological problems, acute illness or stress, and body mass. 
The MNA-SF scores have a strong correlation with the full MNA 
scores, indicating a good clinical accuracy for the MNA-SF in 
predicting malnutrition (220,221). The total scores of the MNA-SF 
screening test range from 0 to a maximum score of 14 points. Those 
who received 11 or fewer points were classified as malnourished or at 
risk of it, whereas well-nourished subjects scored 12 or more points.  
 
Assessment of functional ability (Works III and IV) 
Functional ability was evaluated yearly using the 8-point Instrumental 
Activities of Daily Living (IADL) scale, as introduced by Lawton and 
Brody (222) (Appendix 4). This measure includes questions on using 
telephone, grocery shopping, preparation of meals, housekeeping, 
doing laundry, mode of transportation, taking care of medication and 
managing money. The IADL scale contains eight items, with scores 
from 0 for low function and 8 points for high function. The scores were 
dichotomized to reflect those experiencing significant difficulties in 
daily tasks (IADL score 0–6) and those able to function without severe 
difficulties (IADL score 7–8).  
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Assessment of cognitive capacity (Works III and IV) 
Cognitive capacity was measured yearly by the Mini-Mental State 
Examination (MMSE) test (223) (Appendix 5). This 30-point 
questionnaire samples various functions of cognition, including 
arithmetic, memory and orientation. The maximum score of the 
screening test is 30, meaning good cognitive capacity. In this study, 
cognitive impairment was coded as present if the subject scored 24 or 
less, and no impairment if the score was over 24.  
7.4.4 Other measures 
 
Diagnoses (Work II) 
Clinical diagnoses of diseases in the Kuopio 75+ Study were based on 
patient records and clinical examination by a geriatrician. A structured 
data collection form was used in the examination. Longitudinal 
information about the participants’ medical condition was available 
from primary and secondary care medical records.  
 The diagnoses of dementia and depression were evaluated 
according to DSM-IV criteria (224). Pain was coded as present when 
the participant reported regular pain disturbing daily life or pain at 
rest. In the analyses, heart disease (including coronary heart disease, 
cardiac insufficiency, atrial fibrillation, valvular insufficiency or 
stenosis) and obstructive pulmonary disease (including asthma or 
chronic obstructive pulmonary disease) were recorded as present or 
absent.  
 When counting the number of diagnoses for each participant (Work 
II), claudication, diabetes mellitus, dementia, depression, history of 
stroke, hypertension, pain and obstructive pulmonary disease (asthma 
or chronic obstructive pulmonary disease) were taken into account. 
Correspondingly, coronary heart disease, cardiac insufficiency, atrial 
fibrillation, valvular insufficiency and stenosis were counted as heart 
diagnoses. These disease states were chosen based on previous study 
results and reliable information available from the examination and 
patient records. The number of drugs per diagnosis was counted 
individually by dividing the number of drugs in use and the number 
of diagnosed diseases. 
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Functional Comorbidity Index (FCI, modified for the GeMS study) was used 
in adjusting for comorbidities (Work III). The original FCI is a 
validated scale that predicts physical function of elderly persons (225). 
A modified version included data on 13 conditions available in the 
GeMS: rheumatoid arthritis/other connective tissue disease, 
osteoporosis, chronic asthma/chronic obstructive pulmonary disease 
(COPD), coronary artery disease, heart failure, myocardial infarction, 
Parkinson’s disease/multiple sclerosis, stroke, diabetes, depression, 
visual impairment, hearing impairment and obesity (body mass index 
>30). The presence of each of these conditions gave one score, high FCI 
score meaning greater comorbidity. The information on the presence of 
specific disease/symptom was ascertained via participant self report, 
physician assessment, and medical reports. In addition, in screening 
for diagnosed rheumatoid arthritis/other connective tissue disease, 
chronic asthma, COPD, Parkinson’s disease and multiple sclerosis, the 
Finnish National Prescription and Special Reimbursement Registers 
maintained by the Social Insurance Institution of Finland were used.  
 
Residential status (Works I, II, III and IV) 
Residential status was determined on the basis of living conditions at 
the time of examination. Home living status was coded for subjects 
living in their own home or in sheltered accommodation. Institutional 
care included nursing homes, residential care homes and long-term 
hospital care.  
 
Self-reported health status (Works II, III and IV) 
Self-reported health was measured on a 5-point scale as part of the 
structured study protocol. In order to avoid small subgroups, health 
status was reclassified into three classes: good (=very good/good); 
moderate; and poor (=fairly poor/poor).  
 
Educational level (Work III) 
The classification of educational level follows the number of years of 
completion of a school: lower level comprehensive school or less (0–6 
years) and upper level secondary school or occupational education (7 
or more years).  
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7.5 STATISTICAL ANALYSIS 
In this thesis, the descriptive statistics are expressed as proportions 
and means with standard deviations (SDs). When comparing the 
distributions of categorical variables across polypharmacy groups, 
cross-tabulations were used, and the differences between groups were 
tested using the chi-squared (2) test. For continuous variables, the 
statistical significance in means was determined by the non-parametric 
Kruskal-Wallis test (Works I and II) or ANOVA with post-hoc Tukey 
(Works III and IV). The assumption of normality was assessed 
graphically and tested with the Kolmogorov-Smirnov test. The 
equality of variances was analysed by the Levene test. The paired-
samples t-test was used to compare the differences of means over time. 
P-values 0.05 or less were considered statistically significant.  
 
Work I 
The results are presented as the mean number of drugs in use with 
95% confidence intervals (CIs) and as the proportions of drug users. 
Statistical significance of the changes in drug use between the surveys 
in 1998 and 2003 were analysed by Student’s paired-samples, 
independent samples t-test and Fisher’s exact test.  
 
Work II 
Multinomial logistic regression was used to determine the factors 
associated with polypharmacy and excessive polypharmacy. Potential 
variables were selected on the basis of previous studies reporting risk 
factors for increasing use of drugs in elderly persons. The original 
multivariate model included sex, age group, living alone, self-reported 
health status, claudication, diabetes, dementia, depression, history of 
stroke, hypertension, pain, presence of heart disease and presence of 
obstructive pulmonary disease. Variables were discarded from the 
model if they were not significantly associated with outcomes and 
their removal did not affect the reported associations (change in ORs 
<10%).  
 The final model was fitted for persons (n=472) for whom data were 
available on all measured covariates, including sex, age group, self-
reported health status, diabetes, depression, hypertension, pain, 
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presence of heart disease and presence of obstructive pulmonary 
disease. As a result, 51 persons were excluded because of missing data 
on at least one study variable. The differences between persons 
included and not included in the regression analysis were tested using 

2 test. The results revealed that those excluded experienced 
hypertension more commonly (p=0.037), and depression less 
commonly (p=0.048) than those included in the regression model.  
 
Work III 
A linear mixed model approach was used for analysis of the impact of 
polypharmacy status on MNA-SF, IADL and MMSE scores and the 
progress of these scores over time. The covariates included in the 
analysis were chosen on the basis of previous study results indicating 
the importance of these covariates as risk factors for nutritional 
deficiencies, functional decline or cognitive impairments. The results 
of the linear mixed model are presented as estimated covariate effects 
(β parameters) with standard errors (SEs) and 95% confidence intervals 
(CIs).  
 
Work IV 
The Kaplan-Meier method was used to estimate survival in the 
classified drug categories. Furthermore, the statistical significance of 
differences between survival curves was assessed with the log-rank 
test. The analysis of indicators for mortality was performed using the 
Cox proportional hazard model to calculate crude and adjusted hazard 
ratios (HRs). In addition, 95% confidence intervals (CIs) are reported. 
The assumption of proportional hazards was assessed graphically 
using log-minus-log graphs.  
 
Comparisons between the Kuopio 75+ Study and the GeMS Study  
Independent-samples t-test was used in comparing the mean numbers 
of drugs between age cohorts of 75 years and older. The paired-
samples t-test was used to compare the differences of these means over 
time. The equality of variances was analysed by the Levene test. The 
changes in prevalences according to polypharmacy status were 
analysed by using χ2 test for independent samples (age cohort 
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comparison) and McNemar’s test for dependent samples (longitudinal 
evaluation).  
 
Statistical software 
All data from the Kuopio 75+ Study and the GeMS Study were entered 
into the SPSS statistical software. In the analysis, the latest available 
version of this software was used. The SPSS statistical software for 
Windows (SPSS Inc., Chicago, US) was used to analyse the results of 
Works I (version 11.5), II (version 14.0) and IV (version 14.0). The 
PASW statistical software (SPSS Inc., Chicago, US) for Mac (version 
18.0) was used in Work III as well as in comparisons between the 
Kuopio 75+ Study and the GeMS Study.  
7.6 ETHICAL ISSUES 
Written informed consent was obtained for both the Kuopio 75+ Study 
and the GeMS Study from the participants themselves or their 
relatives. Ethical approval was granted by the ethical committee of the 
Hospital District of Northern Savo and the University Hospital of 
Kuopio.  
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8 Results  
The prospective cohort study designs used in this thesis allow 
reporting results on changes in drug use over time and with ageing in 
Finnish elderly populations. Comparisons between age cohorts give 
information on the changes that happen in the use of drugs among 
aged 75 years and older over time. While the follow-up of survivors in 
two different time periods offer information on typical changes which 
happen in the medication of elderly persons with ageing. In addition, 
associations of polypharmacy with sociodemographic factors, diseases 
and other health-related factors, including self-reported health status, 
nutritional status, functional ability and cognitive capacity, are 
presented. The indicative value of polypharmacy for mortality was 
also analysed.  
8.1 CONTENT OF MEDICATION  
Changes in medication over time and with ageing are presented as 
prevalences for main anatomical and therapeutic drug classes. These 
partly unpublished results include age cohort comparisons among 
those aged 75 years and older (Chapter 8.1.1) and follow-up of 
survivors (Chapter 8.1.2). In the publications of this thesis, the type of 
drugs used is presented for different subpopulations (Works I and II).  
8.1.1 Types of drugs used over time  
The age cohort comparison revealed that cardiovascular drugs were 
the most commonly used drugs, as about four-fifths of those aged 75 
years and older used these drugs in 1998 and 2004 (Table 9). Between 
these years, cardiac therapy became less prevalent (from 55% to 39%), 
whereas more prevalent use was observed for lipid modifying agents 
(from 5% to 27%), ACE inhibitors (19% to 33%) and calcium channel 
blockers (from 16% to 24%) (Appendix 6).  
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An increase was also observed in the use of drugs for blood and 
blood forming organs (from 52% to 63%) and drugs for alimentary 
tract and metabolism (from 52% to 60%) (Table 9). These changes 
occurred mainly because of the increased proportion of those using 
antithrombotic agents (from 48% to 60%), vitamins (from 15% to 23%) 
and mineral supplements (from 11% to 30%) (Appendix 6). A decrease 
in prevalence was found for the use of nervous system drugs (from 
73% to 62%) (Table 9), which was mainly due to a decreased 
proportion of those using analgesics (from 50% to 36%) (Appendix 6). 
Some decrease was also observed  in the use of drugs for the musculo-
skeletal system (from 45% to 36%) (Table 9), especially in the use of 
anti-inflammatory and antirheumatic products (from 36% to 24%) 
(Appendix 6).   
 
Table 9. Drug use according to main anatomical drug classes in age cohort 75 years 
and older in 1998 (Kuopio 75+ Study) and 2004 (GeMS Study) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATC main class 
Kuopio 75+ 
1998 
n=601 
n (%) 
GeMS 
2004 
n=781 
n (%) 
C Cardiovascular drugs 475 (79) 638 (82) 
N Nervous system drugs 438 (73) 483 (62) 
A Alimentary tract and metabolism 311 (52) 469 (60) 
B Blood and blood forming organs 310 (52) 491 (63) 
M Musculo-skeletal system 273 (45) 283 (36) 
G Genito-urinary system and sex 
hormones 
108 (18) 127 (16) 
R Respiratory system 98 (16) 132 (17) 
H Systemic hormonal preparations,  
excl. sex hormones and insulins 
72 (12) 111 (14) 
S Sensory organs 64 (11) 99 (13) 
D Dermatologicals 44 (7) 21 (3) 
J Anti-infectives for systemic use 45 (7) 62 (8) 
L Antineoplastic and immunomodulating 
agents 
8 (1) 14 (2) 
P Antiparasitic products, insecticides 
and repellents 
4 (1) 5 (1) 
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8.1.2 Ageing and the types of drugs used  
During the follow-up of survivors, the use of drugs for blood and 
blood forming organs increased the most (Table 10). The specific drug 
categories behind this increase were antithrombotic agents and 
antianaemic preparations (Appendix 7). Over a five-year period in the 
Kuopio 75+ Study, a remarkable increase was also found in the 
proportion of those using drugs for alimentary tract and metabolism 
(from 44% to 63%) (Table 10). A slight increase (from 58% to 62%) was 
also observed over a three-year period in the GeMS Study. Particularly 
laxatives were a group of drugs that were used more commonly with 
ageing, as the prevalence increased in both studies (from 7% to 
19%/Kuopio 75+ and from 9% to 16%/GeMS) (Appendix 7).  
An increase with ageing was also found in the prevalence of the use 
of cardiovascular drugs, nervous system drugs and anti-infectives for 
systematic use (Table 10). Of specific drugs, the highest increases were 
seen in the use of diuretics, psychoanaleptics and lipid modifying 
agents (Appendix 7). The proportion of those using analgesics 
increased remarkably, from 34% to 50% during the three-year follow-
up of the GeMS Study. In the Kuopio 75+ Study an increase was not 
observed. A slightly decreased prevalence with ageing was observed 
in both studies for the use of musculo-skeletal system drugs (from 47% 
to 41%/Kuopio 75+ and from 34% to 29%/GeMS) (Table 10).  
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Table 10. Drug use according to main anatomical drug classes for survivors (75 years 
and older at baseline) from 1998 to 2003 (Kuopio 75+ Study) and from 2004 to 2007 
(GeMS Study, control group) 
 
 Kuopio 75+ GeMS 
 
 
ATC class 
1998 
n=339 
n (%) 
2003 
n=339 
n (%) 
2004 
n=294 
n (%) 
2007 
n=294 
n (%) 
C Cardiovascular drugs 266 (78) 289 (85) 238 (81) 255 (87) 
N Nervous system drugs 227 (67) 236 (70) 176 (60) 197 (67) 
B Blood and blood 
forming organs 
169 (50) 232 (68) 175 (59) 204 (69) 
M Musculo-skeletal 
system 
159 (47) 140 (41) 101 (34) 84 (29) 
A  Alimentary tract and 
metabolism 
148 (44) 214 (63) 171 (58) 183 (62) 
G Genito-urinary system 
and sex hormones 
59 (17) 47 (14) 49 (17) 58 (20) 
R Respiratory system 49 (14) 46 (14) 49 (17) 47 (16) 
H Systemic hormonal 
preparations, excl. sex 
hormones and insulins 
43 (13) 60 (18) 41 (14) 45 (15) 
S Sensory organs 34 (10) 47 (14) 38 (13) 39 (13) 
D Dermatologicals 28 (8) 9 (3) 9 (3) 9 (3) 
J Anti-infectives for 
systemic use 
20 (6) 51 (15) 13 (4) 24 (8) 
L Antineoplastic and 
immunomodulating 
agents 
1 (0) 7 (2) 7 (2) 9 (3) 
P Antiparasitic products, 
insecticides and 
repellents  
4 (1) 2 (1) 2 (1) 3 (1) 
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8.2 QUANTITY OF DRUG USE  
Quantity of drug use is described by mean numbers of drugs in use in 
separate cohorts of those aged 75 years and older (Chapter 8.2.1) and 
survivors with ageing (Chapter 8.2.2). These results are partly 
unpublished, as the analysis presented in the publications (Works I, 
II, III and IV) concerns different subpopulations.  
8.2.1 Number of drugs in use over time  
Comparison between age cohorts revealed no change in the mean 
number of drugs in use between 1998 (6.9 drugs) and 2004 (6.8 drugs) 
(p=0.807) (Table 11). However, changes occurred in the composition of 
medication. An increase in the mean number was found in the use of 
regularly taken drugs (from 4.3 to 4.8, p=0.003) and vitamins and 
mineral supplements (from 0.4 to 0.7, p<0.001), whereas a decrease 
was seen in the use of drugs taken as needed (from 2.2 to 1.3, p<0.001).  
In both cohorts, women had on average more drugs in use than 
men (7.0 vs. 6.2, p=0.011 in 1998 and 7.3 vs. 5.7, p<0.001 in 2004) (Table 
11). Over time, the mean number of regularly taken drugs increased in 
women (from 4.4 to 5.0, p=0.001), but not in men (from 4.1 to 4.3, 
p=0.595). A significant decrease in mean number over time was 
observed in drugs taken on an as-needed basis, and an increase in 
vitamins and mineral supplements in both sexes.  
Analysis according to age groups found no change in total mean 
number of drugs over time (Table 11). The mean number of as-needed 
drugs decreased and that of vitamins and mineral supplements 
increased over time in all age groups. With regard to regularly taken 
drugs, a statistically significant increase (from 4.2 to 5.1, p=0.003) was 
observed in the age group 80–84 years. Findings were similar in both 
sexes, expect for men aged 85 years and older.   
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The cohort comparison showed that elderly persons living at home 
used about three fewer drugs than persons living in institutions 
(p<0.001 in 1998 and 2004) (Table 12). The increase in the mean 
number of regularly taken drugs was statistically significant only 
among those living at home, while the mean number of as-needed 
drugs decreased and that of vitamins and mineral supplements 
increased for both groups.  
 
Table 12. The mean number of drugs in use by residential status among those aged 75 
years and older in 1998 (Kuopio 75+ Study) and 2004 (GeMS Study) 
Vit+Min =vitamins and mineral supplements 
 
8.2.2 Ageing and the quantity of drugs used  
 
Among survivors, the total mean number of drugs in use increased 
with ageing: from 6.2 to 7.8 drugs (p<0.001) over a five-year period in 
the Kuopio75+ Study and from 6.3 to 7.3 drugs (p<0.001) over a three-
year period in the GeMS Study (Table 13). The mean number of 
regularly taken drugs increased markedly in both follow-ups 
(p<0.001). From 1998 to 2003, the mean number of drugs taken as 
needed decreased from 2.2 to 1.9 (p=0.027) and that of vitamins and 
mineral supplements increased from 0.4 to 0.7 (p<0.001). With regard 
to the use of these drugs, no change was observed from 2004 to 2007 
in the GeMS Study.  
Analysis according to age showed increases in total mean number 
of drugs in all age groups during the follow-ups (Table 13). Similarly, 
Residential 
status/  
Drug use 
1998 2004  
n=601 
Mean (95% CI) 
n=781 
Mean (95% CI) 
 
P-value 
Home n=523 n=700  
  Regularly 4.0 (3.7–4.2) 4.6 (4.3–4.8)   0.001 
  As needed 2.0 (1.9–2.2) 1.2 (1.1–1.3) <0.001 
  Vit+Min 0.4 (0.3–0.4) 0.7 (0.7–0.8) <0.001 
  Total 6.4 (6.1–6.7) 6.5 (6.2–6.8) 0.788 
Institution n=78 n=81  
  Regularly 6.2 (5.6–6.8) 6.5 (5.9–7.2)   0.421 
  As needed 3.1 (2.6–3.7) 2.4 (2.0–2.8)   0.020 
  Vit+Min 0.3 (0.2–0.4) 0.5 (0.3–0.7)   0.044 
  Total 9.6 (8.8–10.5) 9.4 (8.7–10.2)   0.730 
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the mean number of regularly taken drugs showed an increase with 
ageing (p<0.001 for all age groups). A decrease with ageing was 
observed in the mean number of as-needed drugs, but in most age 
groups statistical significance was not reached. For vitamins and 
mineral supplements increased means were observed only in 
survivors in the Kuopio 75+ Study (p<0.001 in all age groups). The 
total mean number of drugs increased with ageing in both follow-ups 
in men and women (Table 14).  
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8.3 CHARACTERISTICS OF POLYPHARMACY  
Changes in polypharmacy status were evaluated by conducting age 
cohort comparison (75 years and older) over time (Chapter 8.3.1) and 
by following up the survivors in these cohorts with advancing age 
(Chapter 8.3.2). Some of these results are unpublished. Polypharmacy 
status for different subpopulations is presented in the publications of 
this thesis (Works I, II, III and IV).  
8.3.1 Polypharmacy over time  
Comparison of age cohorts between 1998 and 2004 did not show any 
changes in distribution of polypharmacy status (Figure 4). Excessive 
polypharmacy was present in every fourth and polypharmacy in every 
third elderly person aged 75 years and older in both study years. The 
analysis of different age groups revealed an increasing prevalence of 
excessive polypharmacy with advancing age over time, whereas the 
proportion of those having polypharmacy remained at the same level 
in all age groups.  
Women had slightly higher prevalences of excessive polypharmacy 
(25% in 1998 and 28% in 2004) than men (22% and 13%, respectively) 
(Figure 5). Polypharmacy did not show any sex differences, as about 
every third man and woman belonged to this group. The difference in 
the prevalence of excessive polypharmacy between those living at 
home (20% in 1998 and 21% in 2004) and in an institution (51% and 
48%, respectively) was remarkable. The prevalence of polypharmacy 
did not show any significant difference between residential statuses.  
 
 
 
  
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Polypharmacy status by age group among those aged 75 years and older in 
1998 (Kuopio 75+ Study) and 2004 (GeMS Study) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Polypharmacy status by sex and residential status among those aged 75 
years and older in 1998 (Kuopio 75+ Study) and 2004 (GeMS Study) 
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8.3.2 Ageing and polypharmacy  
The prevalence of excessive polypharmacy increased from 17% to 31% 
over a five-year period among survivors in the Kuopio 75+ Study and 
from 17% to 26% over a three-year period among survivors in the 
GeMS Study (Figure 6). The proportion of those having polypharmacy 
did not change markedly during the follow-ups. Women reported 
excessive polypharmacy more frequently than men.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Polypharmacy status by sex of survivors in the Kuopio 75+ Study over a 
five-year period (1998–2003) and the GeMS Study (control group) over a three-year 
period (2004–2007)  
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8.4 CORRELATES OF POLYPHARMACY 
The association of polypharmacy with traditional sociodemographic 
factors, self-reported health status and common diseases were 
analysed for home-dwelling elderly persons (Work II). Of other 
health-related factors, the role of nutritional status, functional ability 
and cognitive capacity for polypharmacy is analysed (Work III). The 
main finding of these analyses was that the associated factors are 
partly different for polypharmacy and excessive polypharmacy.  
8.4.1 Demographic factors and health status 
The multivariate analysis of home-dwelling elderly persons showed 
that female sex (OR 2.43, 95% CI 1.27–4.65) and age of 85 years and 
older (OR 2.84, 95% CI 1.41–5.72) are significant factors associated with 
excessive polypharmacy (Table 15). Besides these, moderate self-
reported health status was found to be an independent factor 
associated with excessive polypharmacy (OR 2.05, 95% CI 1.08–3.89). 
Of the total population of home-dwelling elderly persons (n=523), a 
greater proportion of those in the excessive polypharmacy group 
reported their health as poor (32%) compared to persons in 
polypharmacy (19%) and non-polypharmacy (8%) groups (p<0.001) 
(Work II). This finding was confirmed by regression analysis showing 
that poor self-reported health status associate independently with both 
polypharmacy (OR 2.15, 95% CI 1.01–4.59) and excessive 
polypharmacy (OR 6.02, 95% CI 2.55–14.20) after adjusting for 
potential confounders (Table 15).  
8.4.2 Diseases  
Of specific diseases, the presence of obstructive pulmonary disease 
was most strongly associated with polypharmacy (OR 2.79, 95% CI 
1.24–6.25) and excessive polypharmacy (OR 6.82, 95% CI 2.87–16.20) 
(Table 15). In addition, suffering heart disease was also a strong 
correlate of polypharmacy (OR 2.51, 95% CI 1.54–4.08) and excessive 
polypharmacy (OR 4.63, 95% CI 2.45–8.74). For diabetes, depression 
and pain the corresponding risks of polypharmacy and excessive 
polypharmacy were over two-fold compared to non-polypharmacy.  
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Table 15. Factors associated with polypharmacy and excessive polypharmacy among 
home-dwelling participants aged 75 years and older in the Kuopio 75+ Study in 1998 
(n=4721, reference group: non-polypharmacy, 0–5 drugs). 
 
 
 
Factors 
 
Polypharmacy 
6–9 drugs 
OR (95% CI) 
Excessive 
polypharmacy 
10+ drugs 
OR (95% CI) 
Sex   
  Men 1.00 1.00 
  Women 1.57 (0.94–2.63) 2.43 (1.27–4.65) 
Age group    
   75–79 years 1.00 1.00 
   80–84 years 0.85 (0.50–1.43) 1.57 (0.82–2.99) 
   ≥85 years 1.34 (0.73–2.45) 2.84 (1.41–5.72) 
Self-reported health status  
   Good 1.00 1.00 
   Moderate 1.17 (0.71–1.92) 2.05 (1.08–3.89) 
   Poor 2.15 (1.01–4.59) 6.02 (2.55–14.20) 
Diabetes mellitus   
   No 1.00 1.00 
   Yes 2.28 (1.26–4.15) 2.07 (1.03–4.18) 
Depression   
   No 1.00 1.00 
   Yes 2.13 (1.16–3.90) 2.93 (1.51–5.66) 
Hypertension   
   No 1.00 1.00 
   Yes/have had before 1.19 (0.73–1.93) 0.85 (0.48–1.50) 
Heart disease2   
   No  1.00 1.00 
   Yes 2.51 (1.54–4.08) 4.63 (2.45–8.74) 
Obstructive pulmonary disease3 
   No 1.00 1.00 
   Yes 2.79 (1.24–6.25) 6.82 (2.87–16.20) 
Pain   
   No 1.00 1.00 
   Yes 2.69 (1.68–4.30) 2.74 (1.56–4.82) 
Adjusted for all presented variables. 
1n=51 persons excluded because of missing data on at least one study variable 
2 Coronary heart disease (including myocardial infarction, history of coronary angioplasty or 
   bypass operation), cardiac insufficiency, atrial fibrillation, valvular insufficiency or stenosis 
3 Asthma or chronic obstructive pulmonary disease 
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Those home-dwelling elderly persons with excessive polypharmacy 
(n=119) had an average 1.5 (SD 1.1) heart-related diagnoses and 2.7 (SD 
1.1) other diagnoses (Work II). Corresponding means were, 
respectively, 1.2 (SD 1.0) and 2.3 (SD 1.1) in the polypharmacy group 
(n=177), and 0.7 (SD 0.8) and 1.6 (SD 1.0) in the non-polypharmacy 
group (n=227). The mean number of drugs in use per diagnosed 
disease was 3.6 in the excessive polypharmacy group. Persons in the 
polypharmacy group were treated with a mean 2.6 drugs per disease, 
compared with a mean 1.6 drugs per disease in the non-polypharmacy 
group.  
8.4.3 Nutritional status, functional ability and cognitive capacity  
Among survivors in the population-based sample (n=294), excessive 
polypharmacy was associated with a decline in nutritional status, 
functional ability and cognitive capacity, having a 0.62 points lower in 
MNA-SF scores (p=0.001), 0.53 points lower in IADL scores (p<0.001), 
and 1.36 points lower in MMSE scores (p<0.001) compared with the 
non-polypharmacy group (Table 16). These estimates were adjusted 
for age, sex residential status, educational level, self-reported health 
status, modified FCI and time of measuring. Correspondingly, 
polypharmacy was associated only with IADL scores (β=-0.29, 
p=0.002). The rate of decline in scores over time was almost linear in all 
three groups of polypharmacy. In linear mixed model, the interaction 
between polypharmacy status and time of measuring (yearly between 
2004 and 2007) was not statistically significant, which indicates that 
polypharmacy status cannot predict the progress of MNA-SF, IADL 
and MMSE scores over a three-year period. Other factors associated 
with decline in MNA-SF, IADL and MMSE scores were age, 
institutional living and poor self-reported health status (Table 16).  
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8.5 POLYPHARMACY AND MORTALITY 
The prospective follow-up setting of the Kuopio 75+ Study combined 
with separate death data allowed analysing mortality according to 
polypharmacy status in two separate five-year phases (Work IV). The 
results revealed the importance of excessive polypharmacy indicating 
higher mortality, especially among those aged 80 years and older. 
8.5.1 Mortality over a five-year period  
In the first phase for those aged 75 years and older, the mean follow-
up time was 3.62 years between 1998 and 2002. A total of 221 deaths 
occurred during this five-year period, yielding a mortality rate of 37%. 
For participants aged 80 years and older in the second phase, the mean 
follow-up time was 3.79 years between 2003 and 2007. The mortality 
rate over this period was 40% (n=137).  
The Kaplan-Meier survival curves showed a significant difference 
in all-cause mortality between the three polypharmacy groups in both 
phases (log rank test, p<0.001 in both phases) (Figure 7). Participants in 
the non-polypharmacy group had the highest survival rate, whereas 
the shortest survival time was observed in persons with excessive 
polypharmacy. In terms of polypharmacy status, the mortality rate 
from all causes was higher in participants with excessive 
polypharmacy (55% in the first phase, 61% in the second phase) than in 
those with polypharmacy (33% and 40%, respectively) or non-
polypharmacy (27% and 23%, respectively).  
8.5.2 Indicators of mortality 
In the first phase, the univariate model showed an association between 
excessive polypharmacy and mortality (HR 2.53, 95% CI 1.83–3.48) 
(Table 17). However, after adjustment for sex, age, residential status, 
self-reported health status, functional status and cognitive status this 
association attenuated and was no longer statistically significant (HR 
1.28, 95% CI 0.86–1.91). Other variables associated with mortality in 
the multivariate model were age, male sex, difficulties in IADL and 
impaired cognitive status.  
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In the second phase, there was a significant association between 
excessive polypharmacy and mortality (HR 2.23, 95% CI 1.21–4.12) in 
the multivariate model after adjustments (Table 17). Similarly as in the 
first phase, male sex, age and difficulties according to IADL were 
associated with mortality; however, impaired cognitive status was not. 
In addition, poor self-reported health status was associated with 
mortality in the second phase.  
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9 Discussion  
Epidemiological studies conducted during the past decades have 
provided evidence on an increasing use of drugs among elderly 
persons. Previously published studies on drug use are mainly from the 
1980s and 1990s that reveal a clear need for research describing the 
situation in the 2000s. Concerning Finnish elderly populations, this 
thesis offers an overview of changes in overall drug use and 
polypharmacy since the late 1990s. With regard to factors associated 
with polypharmacy, this thesis is the first to report these relations 
separately for polypharmacy and excessive polypharmacy.  
9.1 METHODOLOGICAL CONSIDERATIONS 
This thesis is based on two separate population-based cohort studies 
conducted successively over the periods 1998–2003 (Kuopio 75+ Study) 
and 2004–2007 (GeMS Study) using fairly similar data collection. This 
allowed age cohort comparisons between the studies for those aged 75 
years and older. The longitudinal setting in both studies also offered 
an opportunity to determine changes with ageing in drug use and 
polypharmacy at an individual level.  
9.1.1 Study populations 
In the Kuopio 75+ Study and the GeMS Study, the target populations 
were similarly comprised, encompassing all Kuopio residents aged 75 
years and older at baseline. Furthermore, in both studies the ultimate 
study population comprised a random sample drawn from the target 
population. Approximately one sixth of those belonging to target 
populations (n=700 in the Kuopio 75+ Study and n=1000 in the GeMS 
Study) were randomly selected as study participants, which can be 
considered a large enough sample to provide good representativeness 
of the target population (226). A fairly high participation rate was 
achieved in both studies: 86% (n=601) in the Kuopio 75+ Study and 
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75% (n=377, control group) in the GeMS Study. Because of the high age 
of the participants a significant loss of participants occurred over the 
study periods due to numerous deaths. The death rates were 41% 
(n=248) over a five-year period in the Kuopio 75+ Study and 22% 
(n=110, control group) over a three-year period in the GeMS Study. 
This resulted in a relatively small number of survivors (n=339 and 
n=294, respectively), which limits the power of analyses to some 
extent. Thus, some of the presented results must be regarded as 
preliminary until confirmed by studies with larger study populations.  
 Together, good representativeness of the study samples and a high 
participation rate in the studies allow generalizing the results to the 
target population. The study participants were from a single 
community, so the results on drug use are not directly representative 
of the whole country. However, it is reasonable to assume that drug 
use is fairly similar in the Finnish aged population as a whole. This can 
be argued by the fact that no remarkable differences can be found in 
the proportion of elderly persons receiving reimbursed drugs (93–95%) 
and the mean reimbursement payments per elderly person (550–628 €) 
between five Finnish hospital regions (1). However, it is possible that 
local characteristics may occur in the prescribing patterns of different 
drug items. This is argued by a recent Swedish register-based study 
showing some regional variation in the prevalence of polypharmacy 
for elderly age groups (227). 
9.1.2 Study design and data collection 
The well-designed and structured study protocols of the Kuopio 75+ 
Study and the GeMS Study were the main determinants in gathering 
reliable and valid data on the current health and drug use of the 
elderly participants. The health care personnel, including nurses and 
physicians, taking part in data collection were trained, which is 
essential for uniform and reliable data. It is also plausible that 
combining the know-how of different professionals in conducting a 
research project increases the reliability and validity of collected data. 
 The data concerning current drug use can be considered valid and 
reliable, as the drug information gathered was based on subjects’ own 
report in both studies. With regard the information on psychotropic 
use in the GeMS Study, the agreement between Prescription Register 
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and self-reported data has been observed to be almost perfect (229). 
These findings support the validity of self-reported drug data used in 
this thesis.  
 The recall bias was reduced by checking the reported medication 
from prescriptions and drug containers that the participants were 
asked to bring with them to the interview. Obtaining unbiased data on 
drug use was also increased by asking about current medication, when 
needed, from family members or other caregivers such as home-
nursing service, and checking the accuracy in available medical 
records. Another advantage of collecting drug information directly 
from participants is that besides prescribed drugs also data on the use 
of OTC drugs, vitamins, mineral supplements and even herbal 
remedies could be obtained. This offers a more comprehensive picture 
of total medication compared to information obtained from 
prescription registers based on reimbursed drugs. In addition, a 
prescribed drug does not always mean that this drug is actually used 
by the elderly person (181,230). According to recent review articles on 
adherence to drug therapy, half of the elderly do not adhere to the 
prescribed medication regimen (231,232). It is therefore plausible that 
reliable data concerning actual use of drugs are gathered by face-to-
face interviews.  
 When examining temporal trends in drug use, the length of the 
follow-up period and the number of follow-ups conducted for each 
participant are of considerable relevance. The follow-up time was five 
years in the Kuopio 75+ Study and three years in the GeMS Study. This 
restricted comparing the results on changes in drug use and 
polypharmacy with ageing. Furthermore, information on drug use was 
collected only at two points in the Kuopio 75+ Study, but at four points 
in the GeMS Study. Because of this, crossover in polypharmacy groups 
during the follow-up is weakly manageable in the Kuopio 75+ Study, 
whereas annually collected data on drugs in the GeMS Study offers a 
much better opportunity for crossover control.  
 The main strength of the data used in this thesis was the 
longitudinal design, which allowed describing changes in drug use 
and evaluating temporal relations associated with polypharmacy over 
time and with ageing. Actually, only a limited number of longitudinal 
studies reporting drug use and polypharmacy during the 1990s and 
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2000s have previously been conducted in elderly populations 
(13,14,80). Another strength of this thesis was two separate databases 
using similar protocols in collecting data on drug use. This offered an 
opportunity for age cohort comparison over time between the Kuopio 
75+ Study and the GeMS Study. Concerning the most relevant 
variables used in analyses, the information was collected in the same 
way by structured study forms in both studies. Thus, these uniform 
data from each study year result in good comparability between 
studies.  
 One limitation of the data used concerns incomplete clinical data 
from follow-up periods. In the Kuopio 75+ Study the clinical 
assessments carried out by specialized clinicians were conducted only 
at baseline. With regard to the control group in the GeMS Study, there 
was no examination by a physician; the clinical diagnoses were 
collected from medical records and SII cards. In conclusion, different 
collecting methods between studies and partly incomplete data on 
diagnoses did not allow adjusting for all relevant diseases in the 
publications of this thesis.  
9.2 TEMPORAL TRENDS IN DRUG USE AND POLYPHARMACY 
No remarkable change was observed in the number of drugs in use 
over time from 1998 to 2004; however, the content and composition of 
medication showed some changes. It seems that a higher proportion 
than before of total medication consists of regularly taken drugs. 
Correspondingly, the number of drugs taken on an as-needed basis 
has decreased. Over time, an increase can also be observed in the use 
of vitamins and mineral supplements. Most probably adapted new 
treatment practices for the care of elderly persons are reflected as 
changes in prevalence rates of the use of specific drug classes and 
observed changes in the composition of medication.  
9.2.1 Changes in the types of drugs used 
According to this study, cardiovascular drugs are the most popular 
drugs, which has also been a common finding in other population-
based studies of elderly persons during the 2000s (13,14,83). However, 
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based on the FINRISK population survey, the prevalence of CVDs 
among those aged 65–74 years has declined since 1978 (233). At the 
same time, the expected life expectancy has increased in Finland, being 
now 76 years for men and 83 for women (234). Thus, it can be 
concluded that the onset of CVDs has moved to a more advanced age. 
Indeed, this is supported by some review studies reporting the 
positive effect of preventive drugs and lifestyle modifications on the 
prevalence of cardiovascular diseases in elderly persons over the 
decades (235,236).  
 Our study reported that about four-fifths of the elderly used some 
cardiovascular drugs, which is somewhat higher than reported in 
other Nordic studies conducted in the 1990s (34,53,80,100). The 
difference may reflect the increased opportunities in cardiovascular 
drug treatment and changes in treatment practices during the 2000s. 
Based on this study there is also an observable trend that preventive 
cardiovascular medication has become more common over time. The 
shown changes in cardiovascular drug use patterns are supported by 
US studies that have reported similar prevalences for the use of 
cardiovascular drugs in the 2000s as observed in this study (43,90). In 
the case of cardiovascular drugs, a crude prevalence of drug users 
does not give the whole picture of the magnitude of drug use because 
heart diseases are usually treated with a combination of several drugs. 
This is illustrated by a study reporting that two-fifths of elderly 
persons aged 75 years and older use three or more cardiovascular 
drugs concomitantly (106).  
 Consistent with other studies (43,87,99), common use of nervous 
system drugs was observed in this study. This is problematic, because 
elderly persons are particularly prone to the adverse effects of drugs 
acting on the central nervous system. Even so, overprescribing of these 
drugs has been alarmingly common in Finland (206,237). In the case of 
benzodiazepines, it has been estimated that up to 15% of home-
dwelling elderly persons are using these drugs without a diagnosis of 
any mental disorder (113). Achieving persistent reductions in the use 
of psychotropics among elderly persons by medication assessments 
has proven to be difficult (238,239). Nonetheless, this study reported a 
promising decreasing prevalence over time in the use of nervous 
system drugs among elderly persons aged 75 years and older. It may 
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be that the public debate on the use of psychotropics in the treatment 
of elderly persons has influenced prescribing habits positively.  
 The observed increase in the consumption of drugs for alimentary 
tract and metabolism was mainly due to increased use of vitamins and 
mineral supplements. Of these, especially the use of calcium 
supplements and vitamin D has become more frequent over the past 
years (240). It is probable that the use of vitamin D will onwards 
increase as a consequence of recently published Finnish nutritional 
recommendations suggesting an all-year 20 μg vitamin D dose for 
persons aged 60 years and older (241). Drugs for blood and blood 
forming organs was the other main anatomic class in which an 
increase in prevalence was detected over time and with ageing. This 
occurred mostly due to an increased use of antithrombotic agents, of 
which other Finnish studies have reported the use of preventive low-
dose ASA to increase most rapidly (106,240). A slight decrease over 
time and with ageing was observed in the use of drugs for the 
musculo-skeletal system. This finding is consistent with other studies 
reporting some pain symptoms to decline in frequency with ageing, 
resulting in decreased consumption of analgesics (86,242,243). It has 
also been argued that clinicians give a low priority to pain compared 
with other medical problems, which leads to undertreatment of pain 
symptoms in the elderly (244).  
9.2.2 High number of drugs in use 
This study found an average of almost seven drugs in use in elderly 
persons aged 75 years and older. A high number of drugs in use has 
also been noted in other studies for the same age cohort during the 
1990s, but the reported mean numbers have generally been lower than 
those found in this study (52,55,100). Research on quantity of drug use 
has been limited in the 2000s. A Swedish study conducted in the early 
2000s reported remarkable lower means than found in this study (105). 
However, these figures are not fully comparable with our study as 
none of the referred studies included vitamins and mineral 
supplements when reporting the mean number.  
 Age cohort comparison revealed that the mean number of drugs in 
use has remained constant from 1998 to 2004. The reason for this is not 
clear, but it may be due to the range of new pharmacotherapies 
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launched to the market during the late 1980s and 1990s (12). Several of 
these drugs were for diseases typical for elderly persons, such as 
dementia, osteoporosis and hyperlipidaemia. Thereafter, during the 
2000s, the trend of new drug launches has ceased. However, there are 
also inconsistent results that have showed continuously increasing 
prevalence of polypharmacy and excessive polypharmacy from 2005 to 
2008 in Swedish elderly age cohorts (245).  
 The mean number of regularly taken drugs increased and that of 
as-needed drugs decreased during the study period over time and 
with ageing. Previous longitudinal cohort studies describing temporal 
trends for drugs taken regularly and as needed cannot be found. 
Furthermore, direct comparisons of the mean number with cross-
sectional studies are complicated because of non-uniform classification 
of drugs; most studies have differentiated between prescription and 
OTC drugs, whereas this study classified regularly taken and as-
needed drugs separately. However, some cross-sectional studies 
conducted in elderly persons during the 2000s have reported a mean 
between four and five for prescription drugs and a mean of one and 
half for OTC drugs (61,69), which are consistent with the mean 
numbers reported in this study.  
 As expected, elderly persons living in institutional care used 
significantly more drugs than those living at home; therefore, in line 
with recent studies, institutional residence can be seen as an indicator 
of a high number of drugs in use (170,246,247). A Dutch study 
reported a minor, but statistically significant, increase in the mean 
number of drugs in use six weeks after admission into a nursing home 
(248). It is evident that institutional-living elderly persons suffer from 
several diseases needing drug treatment. On the other hand, this poses 
a major concern regarding the quality of drug treatment, as the high 
number of drugs in use increases the risk of drug-induced problems 
(14,249,250). It has been estimated that one in ten hospitalizations of 
elderly persons is medication-related (251). For clinicians, finding the 
right balance between benefits and harms of drug treatment is 
challenging when caring for elderly persons living in institutional care.  
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9.2.3 Increasing occurrence of polypharmacy  
The fairly high cross-sectional prevalences of polypharmacy and 
excessive polypharmacy found in this study are pretty congruent with 
other recent studies examining overall drug use in elderly populations 
(44,68,141). In general, the estimates of polypharmacy that have 
reported mainly during the 1990s showed higher prevalences in the 
Nordic countries (13,14,53,80) and the US (63,67,138) than in other 
countries (35,55,66). In Finland and other Nordic countries, one factor 
contributing to the increase in polypharmacy and excessive 
polypharmacy may be the reimbursement system, which allows for 
universal access to prescription drugs by refunding and subsidizing 
the costs of drugs for all citizens equally (252). During the 2000s 
differences in prevalences between countries have decreased, as most 
Western studies have reported prevalences similar to this study. 
 In this study, the prevalence of polypharmacy and excessive 
polypharmacy increased with ageing, but not over time. It stands to 
reason that the presence of diseases increases with ageing, leading to 
more prevalent polypharmacy and excessive polypharmacy. It might 
be that constant prevalences of polypharmacy and excessive 
polypharmacy over time are the fairly established drug treatment 
patterns in the case of most diseases that elderly persons suffer from.  
9.3 POLYPHARMACY AND ITS CORRELATES 
This study revealed that the factors associated with polypharmacy and 
excessive polypharmacy in elderly persons are not uniform. With 
regard to the associations found, previous studies have reported partly 
parallel results solely for polypharmacy; however, this study was the 
first to report separate associations for excessive polypharmacy.  
9.3.1 Sociodemographic correlates of polypharmacy 
In line with several other studies, the current study revealed female 
sex and advanced age to be important factors associated with 
increasing use of drugs. When using five or more drugs as a definition 
of polypharmacy, several studies have shown these two demographic 
factors to be strong correlates of polypharmacy (34,96,151,163). 
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Interestingly, this study noted that female sex and age of 85 years and 
older were actually only associated with excessive polypharmacy. The 
findings regarding these correlates of excessive polypharmacy are 
corroborated by a large Swedish register-based study conducted 
among elderly population of the same age as in this study (44).  
 This study, like several previous ones (55,105), found that living in 
institution is associated with increasing occurrence of polypharmacy. 
The association with excessive polypharmacy would be even stronger, 
but the rate of risk of excessive polypharmacy for elderly persons 
living in institutions has not been reported in this study. However, the 
results of this study showed remarkable increase in drug use among 
those survivors who had moved from home to institution during the 
study period. 
 The role of socioeconomic factors, including income, education and 
occupation, for polypharmacy was not examined in this study because 
of incomplete data concerning these variables. In the light of recently 
published studies, it seems reasonable to assume that socioeconomic 
determinants are relevant factors associated with polypharmacy. There 
is at least evidence of low education (167) and relative deprivation (38) 
as factors associated with greater risk of polypharmacy. With regard to 
income and occupation, a few previous studies have not found an 
association with polypharmacy (105). Based on the literature review of 
this thesis, the relevance of socioeconomic factors for polypharmacy is 
poorly examined; thus, more research is needed in this area.  
9.3.2 Relevance of diseases and symptoms for polypharmacy 
This study found asthma/COPD, heart diseases, diabetes, depression 
and pain to be important factors associated with both polypharmacy 
and excessive polypharmacy. The present findings on polypharmacy 
relations with diabetes and different kind of heart diseases are in 
concordance with several previous studies conducted among 
community-dwelling (62,66,108,142) and hospitalized (48,107,146) 
elderly populations. Previously reported results on polypharmacy 
association with pulmonary diseases and depression are somewhat 
controversial; some studies have reported quite strong associations 
(48,146), whereas others have shown no statistically significant 
associations (49,66,107,142).  
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 Regarding the occurrence of pain and the use of analgesics, the 
results found in this study are partly conflicting. Pain was shown to 
associate with polypharmacy, but regardless of that, a slight decrease 
was observed in the use of drugs for the musculo-skeletal system over 
time and with ageing. The correlation between polypharmacy and 
pain symptoms is in line with previous studies examining the same 
age cohorts of elderly persons (107,119). Suffering from pain has also 
shown to correlate with poor overall health status (119), which is an 
important indicator of polypharmacy (65,80,173). A possible 
explanation for a decrease in the use of drugs for the musculo-skeletal 
system is that elderly persons are reluctant to report pain-related 
symptoms because of the belief that pain is a necessary part of life 
when growing old. Another potential reason for the observed 
decreasing trend in the use of analgesics among Finnish elderly 
persons are training programs and published current care guidelines 
related to appropriate use of NSAIDs (253).  
 The results showed that elderly persons with polypharmacy or 
excessive polypharmacy used about three drugs per diagnosis. 
Obviously this is not a measure of treatment rationality, but the 
findings emphasize the need for reassessment of medication so that it 
is based on proper diagnosis. The results also suggest that drug 
treatment is more symptom- than diagnosis-based. Evidence for the 
rationality of combination therapy in the elderly is still mostly lacking. 
Instead, there are findings indicating high probability of potentially 
inappropriate drug use in elderly multi-dose users (254). Although it 
may not be reasonable to avoid polypharmacy, especially in patients 
with several chronic diseases, polypharmacy is often a potential risk 
factor for medication problems. In addition, low adherence to 
prescribed medication limits the benefits of current drug treatment, 
calling for new efforts to assist patients to adhere to their drug 
regimens (255).   
9.3.3 Polypharmacy relation with health status and its determinants 
The results of this study showed that poor self-reported health is a 
significant factor associated with both polypharmacy and excessive 
polypharmacy, whereas moderate health status is only associated with 
excessive polypharmacy. These findings are consistent with previous 
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studies concerning polypharmacy (51,61,62), but the association with 
excessive polypharmacy has not been reported previously. Decreased 
health status is most obviously reported due to increased occurrence of 
morbidity and gradual deterioration of body functions with ageing. 
However, decreased health status might also reflect undiagnosed 
diseases or otherwise unsuccessful treatment that is not based on 
proper diagnosis. This interpretation is supported by a Dutch study 
showing that paradoxically, the probability of underprescribing 
increases with the number of drugs in use in elderly persons (45). 
Further studies on the association of health status with polypharmacy 
that take into account the rationality of drug treatment are needed.  
 Besides health status, this study examined the relevance of 
commonly used indicators of weakened health status and decreased 
overall well-being, including nutritional status, functional ability and 
cognitive capacity, for polypharmacy. The results showed excessive 
polypharmacy to be strongly associated with nutritional deficiencies, 
functional disabilities and impaired cognition in elderly persons. 
During the three-year follow-up there was an almost linear decrease in 
scores of validated screening tests examining the risk of malnutrition 
and remaining functional and cognitive capacity, which corresponds 
to the results of other studies (190,256,257). In this study, the most 
pronounced changes in nutritional status, functional ability and 
cognitive capacity over time were found in those with excessive 
polypharmacy. Of them, half were malnourished or at risk of it, three 
out of four had difficulties in daily tasks and half had impaired 
cognition at the end of the follow-up. These three determinants have 
proven to be relevant predictors of hospitalization (258-260). Thus, it is 
reasonable to suggest that among elderly persons, excessive 
polypharmacy is a relevant sign of possible difficulties in managing 
everyday life tasks.  
 The results of this study regarding the association between 
excessive polypharmacy and malnutrition are fairly congruent with 
earlier studies showing low scores in full MNA screening test and 
weight loss to associate with an increasing number of drugs in use 
among elderly persons (58,200). There are two potential explanations 
for this association. Firstly, changes in appetite may appear as a result 
of physical diseases or psychological stress (188). Secondly, some 
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medications increase the possibility of dry mouth (e.g. anticholinergics) 
(261) and nausea (e.g. acetylcholine esterase inhibitors) (262), and may 
cause bitter metallic taste (e.g. eszopiclone/zopiclone) (263, 264). These 
unwanted events may lead to poor appetite and eating difficulties, 
increasing further the risk of malnutrition.  In order to identify elderly 
persons at risk of weight loss and malnutrition, regular comprehensive 
assessments are recommended, especially for those needing assistance 
in their daily living (265). 
 The current findings on the association of polypharmacy and 
excessive polypharmacy with declined IADL scores are in accordance 
with a German study that defined polypharmacy as the use of five or 
more prescribed drugs (61). However, this is the first study to report 
this association for those with excessive polypharmacy. Association 
was observed between polypharmacy and declined functional ability 
in a Japanese study (142), while an inverse association was found in a 
US study (108). It is possible that specific drug classes can partly 
explain declined functional ability. This may be the case of 
psychotropics, as they cause dizziness and tiredness, especially in 
elderly persons, which can impair balance and lead to falls (266-268). 
Nonetheless, research on the association between polypharmacy and 
functional ability is scarce. Further studies are needed to confirm the 
reported association of polypharmacy and excessive polypharmacy 
with functional decline found in this study.  
 Evidence on the association of excessive polypharmacy with 
declined cognition was presented in this study for the first time. Prior 
studies have only reported that persons with dementia use more drugs 
than those without dementia (47,142). The fact that comorbidities 
requiring drug treatment are common in elderly persons with 
dementia (269) suggests that research on the association between 
polypharmacy and cognitive capacity is needed. 
   
9.3.4 Polypharmacy as an indicator of mortality 
The present study confirmed excessive polypharmacy to be an 
indicator of 5-year mortality in elderly persons aged 80 years and older. 
The trend was similar for polypharmacy, but the association did not 
remain significant after adjustments. Previously, studies concerning 
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polypharmacy and mortality (120,215,216) have not differentiated 
between polypharmacy and excessive polypharmacy. These studies 
found that polypharmacy is associated with mortality in population-
based (216) and hospital-based (120) samples of elderly persons.  
 It is obvious that in elderly persons, polypharmacy occurs mostly 
due to increased morbidity with ageing. Concerning previous studies, 
it is of interest that polypharmacy has remained a weak independent 
factor associated with mortality even after being adjusted for several 
relevant comorbidities (120,216). The observed associations of this 
study could not be adjusted for comorbidities due to incomplete data 
on diagnosed diseases; however, other factors reflecting current health 
status, including residential status, self-reported health, cognitive 
capacity and functional ability were used in adjusting. It is reasonable 
to claim that institutional living and declines or limitations in the three 
health-related factors mentioned are fairly good markers of worsened 
overall health. This conclusion is supported by the observations of this 
study showing impaired cognitive status and declined functional 
status to associate with mortality. Thus, the current study adds 
evidence to the role of cognitive and functional status as predictors of 
mortality (270-272).  
 In the light of previous studies, it seems reasonable to assume that 
inappropriate medication can at least partly explain the indicative 
value of excessive polypharmacy for mortality observed in this study. 
This interpretation can be argued by a recent study which found that 
elderly persons using five or more drugs are more than three times 
more likely to receive inappropriate drugs than those taking fewer 
drugs (70). Furthermore, adverse drug effects as a result of 
inappropriate prescribing have been shown to lead to hospitalizations 
and increased mortality (273). On the other hand, polypharmacy may 
also be a rational way of treatment when implemented properly, with 
regular reviews of medication. However, no conclusions about the 
appropriateness or rationality of the medication taken by the 
participants in this study can be made because of missing 
comprehensive medication reviews.  
 Despite the lack of evidence on the quality of drug treatment, the 
findings of this study concerning polypharmacy and mortality call for 
interventions to ensure optimal medication for elderly persons. 
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Unnecessary drugs should be discontinued so that all drugs an elderly 
person is taking are effective and have the correct indication without 
any therapeutic duplication (11). Optimizing medication may also 
include prescribing new drugs for untreated conditions (142). Based on 
the results of this study, these efforts should be targeted especially 
towards elderly persons using ten or more drugs concomitantly in 
order to prevent adverse outcomes, including mortality associated 
with polypharmacy. Medication assessment by multidisciplinary 
teams seems to be effective for optimizing medication and preventing 
unnecessary polypharmacy, with particular benefits in terms of drug-
drug interactions (157,160,250,251,274). This suggests that increasing 
co-operation between different health care professionals would be 
worthwhile in Finnish health care as well.  
9.4 POLYPHARMACY IN MEDICAL PRACTICE 
This thesis shows that polypharmacy and excessive polypharmacy are 
very prevalent in elderly persons, especially among the most 
vulnerable persons. It is probable that polypharmacy can to some 
extent be seen as an iatrogenic problem when adverse effects caused 
by drugs are not recognized as such, resulting in new unnecessary 
prescriptions (275-277). In addition, polypharmacy and excessive 
polypharmacy may be consequences of unnecessary drug use resulting 
from unnecessary repeat prescribing and lack of monitoring. Thus, in 
preventing possible unnecessary polypharmacy, making oneself 
conversant with the complicated process of ageing and developing 
monitoring systems will help to achieve more appropriate drug 
treatment for elderly persons. 
 Based on the findings of this study, it can be stated that impaired 
overall health seems to accumulate for those having excessive 
polypharmacy. This emphasizes the idea of treating elderly persons 
comprehensively by a multidisciplinary team including geriatricians, 
nurses, pharmacists, nutritionists and physiotherapists. Concerning 
drug treatment, co-operation between physicians and pharmacists has 
proven to reduce the occurrence of polypharmacy and to diminish 
drugs costs (159,160,278). Increased training of physicians and other 
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health care professionals has a crucial impact on treatment practices 
and the implementation of drug treatment for elderly persons. A 
recently published European silver paper on the current situation and 
future needs in caring for elderly persons calls for multiprofessional 
aspects that presume good knowledge of ageing-related issues on the 
part of health care professionals (279). In Finland, more detailed 
proposals concerning the development of geriatric care and elderly 
care were published in 2006 by the Ministry of Social Affairs and 
Health (280). In brief, this report proposed increasing the amount of 
research in geriatric care and pharmacotherapy for health care 
professionals. The practical impact of these proposals is hard to assess 
because of the short time period since they were published. 
 The association of polypharmacy with particular diseases may 
result, at least in part, from current treatment guidelines that 
recommend the use of multiple drugs in the care of these disease states 
(281). These guidelines should not be adopted when caring for elderly 
persons, because the guidelines are mainly based on evidence obtained 
from studies in middle-aged populations with only a small evidence 
base relating to the care of frail elderly persons (282). In the case of 
elderly persons, it is even recommended that some drugs suggested in 
these treatment guidelines should be avoided, according to consensus-
based criteria for potentially inappropriate drug use in elderly persons 
(283-286). Recently, the Finnish Medicines Agency also published a 
database on medication for elderly persons to support clinical 
decision-making in primary care settings (287). 
Concerning the quality of drug treatment, developing services 
offering comprehensive medication assessments may have an impact 
on the current state of overall drug use (288). Previous studies have 
shown an association of polypharmacy with increasing occurrence of 
drug-related problems, including inappropriate medication, 
undertreated conditions, drug interactions and adverse drug reactions 
(10,168). Some intervention studies have reported reduced occurrence 
of polypharmacy as a result of medication reviews conducted by a 
physician (139,210,289) or together with pharmacists (290). These 
findings suggest that medication assessments should be implemented 
more often (291), especially for elderly persons having polypharmacy 
(292). In Finland, the Ministry of Social Affairs and Health 
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recommends medication assessments at regular intervals, at least on 
an annual basis, for all elderly primary care patients (293). Findings of 
this study support this idea of regular assessments of medication 
among the elderly as an intergral part of comprehensive care for 
elderly persons. 
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10 Conclusions  
1. Content of medication 
Cardiovascular drugs are the most commonly used drugs by elderly 
persons. Over time and with ageing, the use of antithrombotic agents, 
vitamins and mineral supplements increased, whereas the use of 
nervous system drugs decreased.  
 
2. Quantity of drug use 
From 1998 to 2004 the total mean number of drugs in use remained as 
seven drugs. Changes occurred in the composition of medication: 
mean number of regularly taken drugs, vitamins and mineral 
supplements increased, whereas the mean number of as needed taken 
drugs decreased. Women use on average more drug than men. Those 
in institutional care use about three drugs more than those living at 
home.  
 
3. Characteristics of polypharmacy 
Every fourth elderly person uses 10 or more drugs (excessive 
polypharmacy) and every third uses 6–9 drugs (polypharmacy). With 
ageing, the proportion of those with excessive polypharmacy 
increases.  
 
4. Polypharmacy and morbidity 
Every diagnosed disease is treated with 3.6 drugs in the excessive 
polypharmacy and 2.6 drugs in the polypharmacy group. 
Asthma/COPD, presence of heart disease, diabetes, depression and 
pain correlate with polypharmacy and excessive polypharmacy. 
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5. Association of polypharmacy with demographics and overall 
health status 
Demographic and health status factors associated with polypharmacy 
and excessive polypharmacy are not uniform. Female sex and age of 85 
years and older correlate with excessive polypharmacy, but not with 
polypharmacy. Poor self-reported health status is strongly associated 
with both polypharmacy and excessive polypharmacy.  
 
6. Association of polypharmacy with determinants of declined 
health 
Excessive polypharmacy is an important factor associated with 
declined nutritional status, functional ability and cognitive capacity; 
however, the changes in these three outcomes with ageing cannot be 
predicted by polypharmacy status. Overall worsening health of an 
individual was observed as an accumulation of excessive 
polypharmacy, nutritional deficiencies, functional inability and 
cognitive impairments. 
 
7. Polypharmacy and mortality  
Excessive polypharmacy, but not polypharmacy, is an indicator of 
mortality in elderly persons.  
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11 Implications for the 
Future 
11.1 PRACTICAL IMPLICATIONS 
1. Annual assessments of medication 
An annual assessment of medication as a routine part of the treatment 
of elderly persons in order to optimise medication and avoid possible 
unnecessary polypharmacy is recommended. 
 
2. Multiprofessional teams in the care 
A multidisciplinary team including physicians, nurses, pharmacists, 
nutritionists and physiotherapists are needed in a more 
comprehensive treatment and care of elderly persons. 
 
3. Treatment guidelines for elderly persons 
To achieve optimal drug treatment more evidence-based and tailored 
guidelines for elderly persons are needed.  
 
4. Training for health care professionals 
There is a need to increase the training of health professionals about 
the basic principles of ageing and the implementation of optimal drug 
treatment. 
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11.2 FUTURE DIRECTIONS FOR RESEARCH 
1. Rationality of polypharmacy 
More research is needed on the relationship between polypharmacy 
and unnecessary drug treatment or other drug-related problems. 
 
2. Intervention studies 
The findings of this study call for intervention studies to ensure 
optimal medication of elderly persons suffering from several diseases.  
 
3. Qualitative studies on drug use patterns 
Qualitative research on elderly persons’ beliefs about drugs is 
important because beliefs ascertain whether drugs are used as ordered. 
 
4. Relation between prescribed and used drugs 
There is a clear need to study adherence in elderly populations as all 
prescribed drugs are not used.  
 
5. Economic aspects of polypharmacy 
The economic aspect of polypharmacy is lacking.  
 
6. Polypharmacy and service use 
The role of polypharmacy in the consumption of health services 
requires more research as unnecessary polypharmacy may cause 
adverse drug effects or other harms linked to drug treatment that may 
lead to increased use of health services.  
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Appendix 1. Kuopio 75+ Study form (only essential parts concerning drug data are
presented)
MEDICATION
Do you use any regular medication?
     0 no
     1 yes
Drug name and strength Dose Indication ATC code
Do you use any as needed taken medication?
     0 no
     1 yes
Drug name and strength Dose Indication ATC code
Do you use regularly any vitamins, mineral supplements or herbal remedies?
(used at least once a week)
     0 no
     1 yes
Drug name Dose Indication ATC code
Appendix 2. GeMS Study form (only essential parts concerning drug data are presented)
MEDICATION
Do you use any regular medication?
     0 no
     1 yes
Drug name Strength Dose Indication
Do you use any as needed taken medication? (used at least once a week)
     0 no
     1 yes
Drug name Strength Dose Indication
Do you use regularly any vitamins or mineral supplements?
     0 no
     1 yes
Drug name Dose Indication
Do you use regularly any herbal remedies?
     0 no
     1 yes
Drug name Dose Indication
Mini Nutritional Assessment
 MNA®
   
Last name:      First name: 
Sex:   Age:   Weight, kg:  Height, cm:  Date:  
Complete the screen by filling in the boxes with the appropriate numbers. Add the numbers for the screen. If score is 11 or less, continue with the 
assessment to gain a Malnutrition Indicator Score.  
G
H
I
Screening score 
(subtotal max. 14 points) 
12-14 points: Normal nutritional status 
8-11 points: At risk of malnutrition 
0-7 points: Malnourished
For a more in-depth assessment, continue with questions G-R 
Ref.
Has food intake declined over the past 3 months due to 
loss of appetite, digestive problems, chewing or 
swallowing difficulties? 
0 = severe decrease in food intake 
1 = moderate decrease in food intake 
2 = no decrease in food intake 
Weight loss during the last 3 months 
0 = weight loss greater than 3kg (6.6lbs) 
1 = does not know 
2 = weight loss between 1 and 3kg (2.2 and 6.6 lbs) 
3 = no weight loss 
Mobility 
0 = bed or chair bound 
1 = able to get out of bed / chair but does not go out 
2 = goes out 
Has suffered psychological stress or acute disease in the 
past 3 months? 
0 = yes 2 = no 
Neuropsychological problems 
0 = severe dementia or depression 
1 = mild dementia 
2 = no psychological problems 
Body Mass Index (BMI) (weight in kg) / (height in m2)
0 = BMI less than 19 
1 = BMI 19 to less than 21 
2 = BMI 21 to less than 23 
3 = BMI 23 or greater  
How many full meals does the patient eat daily? 
0 = 1 meal 
1 = 2 meals 
2 = 3 meals 
Selected consumption markers for protein intake 
 At least one serving of dairy products 
(milk, cheese, yoghurt) per day yes no 
 Two or more servings of legumes 
or eggs per week   yes no 
 Meat, fish or poultry every day  yes no 
0.0 = if 0 or 1 yes 
0.5   = if 2 yes 
1.0   = if 3 yes                 . 
Consumes two or more servings of fruit or vegetables per day? 
0 = no 1 = yes 
How much fluid (water, juice, coffee, tea, milk...) is consumed per 
day? 
0.0 = less than 3 cups 
0.5 = 3 to 5 cups 
1.0 = more than 5 cups                . 
Mode of feeding 
0 = unable to eat without assistance 
1 = self-fed with some difficulty 
2 = self-fed without any problem 
Self view of nutritional status 
0 = views self as being malnourished 
1 = is uncertain of nutritional state 
2 = views self as having no nutritional problem 
In comparison with other people of the same age, how does the 
patient consider his / her health status? 
0.0 = not as good 
0.5 = does not know 
1.0 = as good 
2.0 = better                   . 
Mid-arm circumference (MAC) in cm 
0.0 = MAC less than 21
0.5 = MAC 21 to 22 
1.0 = MAC 22 or greater                . 
Calf circumference (CC) in cm 
0 = CC less than 31 
1 = CC 31 or greater 
A
B
C
D
J
E
F
Screening
Assessment 
Lives independently (not in nursing home or hospital) 
1 = yes 0 = no 
Takes more than 3 prescription drugs per day 
0 = yes 1 = no 
Pressure sores or skin ulcers 
0 = yes 1 = no
Vellas B, Villars H, Abellan G, et al. Overview of MNA® - Its History and Challenges.
J Nut Health Aging 2006; 10: 456-465. 
Rubenstein LZ, Harker JO, Salva A, Guigoz Y, Vellas B. Screening for 
Undernutrition in Geriatric Practice: Developing the Short-Form Mini Nutritional 
Assessment (MNA-SF). J. Geront 2001; 56A: M366-377. 
Guigoz Y. The Mini-Nutritional Assessment (MNA®) Review of the Literature – What 
does it tell us? J Nutr Health Aging 2006; 10: 466-487. 
® Société des Produits Nestlé, S.A., Vevey, Switzerland, Trademark Owners 
© Nestlé, 1994, Revision 2006. N67200 12/99 10M 
For more information: www.mna-elderly.com
K
L
M
N
O
P
Q
R
Assessment (max. 16 points)    . 
Screening score     . 
Total Assessment (max. 30 points)    .
Malnutrition Indicator Score 
24 to 30 points   normal nutritional status 
17 to 23.5 points   at risk of malnutrition 
Less than 17 points   malnourished 
Appendix 3. Mini Nutritional Assessment (MNA) test
Appendix 4. Instrumental Activities of Daily Living (IADL) scale
Scores
Ability to use telephone
1. Operates telephone on own initiative; looks up and
dials numbers, etc.
1
2. Dials a few well-known numbers 1
3. Answers telephone but does not dial 1
4. Does not use telephone at all 0
Shopping
1. Takes care of all shopping needs independently 1
2. Shops independently for small purchases 0
3. Needs to be accompanied on any shopping trip 0
4. Completely unable to shop 0
Food preparation
1. Plans, prepares and serves adequate meals independently 1
2. Prepares adequate meals if supplied with ingredients 0
3. Heats, serves and prepares meals or prepares meals but does
not maintain adequate diet.
0
4. Needs to have meals prepared and served 0
Housekeeping
1. Maintains house alone or with occasional assistance
(e.g. “heavy work domestic help”)
1
2. Performs light daily tasks such as dishwashing, bed making 1
3. Performs light daily tasks but cannot maintain acceptable level
of cleanliness
1
4. Needs help with all home maintenance tasks 1
5. Does not participate in any housekeeping tasks 0
Laundry
1. Does personal laundry completely 1
2. Launders small items; rinses stockings, etc. 1
3. All laundry must be done by others 0
Mode of transportation
1. Travels independently on public transportation or
drives own car
1
2. Arranges own travel via taxi, but does not otherwise use public
transportation
1
3. Travels on public transportation when accompanied by another 1
4. Travel limited to taxi or automobile with assistance of another 0
5. Does not travel at all 0
Responsibility for own medications
1. Is responsible for taking medication in correct dosages
at correct time
1
2. Takes responsibility if medication is prepared in advance in
separate dosage
0
3. Is not capable of dispensing own medication 0
Ability to handle finances
1. Manages financial matters independently (budgets, writes
checks, pays rent, bills goes to bank), collects and keeps track of
income
1
2. Manages day-to-day purchases, but needs help with banking,
major purchases, etc.
1
3. Incapable if hangling money. 0
Appendix 5. Mini Mental State Examination (MMSE) test
Orientation to time
Incorrect Correct
What is the year? 0 1
What season is it? 0 1
What is the month? 0 1
What is today’s date? 0 1
What is the day of the week today? 0 1
Orientation to place
What country are we in? 0 1
What province are we in? 0 1
What county/city are we in? 0 1
What place is this? (home, hospital, etc.) 0 1
What room is this? (other exact place) 0 1
Immediate recall
I tell you three short words. After this I ask you to second each of these.
The words are ROSE, BALL, KEY. Please repeat these words.
Correct in first time?
ROSE 0 1
BALL 0 1
KEY 0 1
Please remember these words. I will ask these again soon.
Attention
Begin with 100 and count backwards by 7. If the person forget the
question it can be repeated. Paper and pencil are now allowed.
93 0 1
86 0 1
79 0 1
72 0 1
65 0 1
Delayed verbal recall
What were those three words that I asked to remember?
ROSE 0 1
BALL 0 1
KEY 0 1
Naming
Show the individual a wristwatch and ask him/her what is it. Repeat
with pencil.
WATCH 0 1
PENCIL 0 1
Repetition
Listen carefully and repeat following.
THE STUDENT SOLVED
A COMPLICATED TASK
0 1
3-stage command
Listen the following instructions and do what is asked.
Take the paper in your hand, fold it in half, and put it on your knees.
TAKES 0 1
FOLD 0 1
KNEES 0 1
Reading
Here is a sentence. Read it aloud and do what is said.
CLOSE YOUR EYES 0 1
Writing
Write a whole short sentence to this line.
Verb, substantive and predicative
are present.
0 1
Copying
Copy a design of two inserted shapes. 0 1
One point is awarded for correctly copying the shapes. All angles on
both figures must be present, and the figures must have one
overlapping angle.
Appendix 6. Drug use according to ATC classification in separate cohorts of elderly persons
aged 75 years and older in 1998 (Kuopio 75+ Study) and 2004 (GeMS Study)
ATC code
Kuopio 75+
n=601
GeMS
n=781
C Cardiovascular system 475 (79) 638 (82)
C01 Cardiac therapy 332 (55) 303 (39)
C02 Antihypertensives 4 (1) 3 (0)
C03 Diuretics 216 (36) 240 (31)
C04 Peripheral vasodilators 15 (2) 5 (1)
C05 Vasoprotectives 11 (2) 4 (1)
C07 Beta blocking agents 260 (43) 395 (51)
C08 Calcium channel blockers 95 (16) 188 (24)
C09 Agents acting on the renin-angiotensin
        system
115 (19) 257 (33)
C10 Lipid modifying agents 30 (5) 215 (27)
N Nervous system 438 (73) 483 (62)
N02 Analgesics 299 (50) 279 (36)
N03 Antiepileptics 9 (1) 15 (2)
N04 Anti-Parkinson drugs 12 (2) 14 (2)
N05 Psycholeptics 252 (42) 304 (39)
N06 Psychoanaleptics 76 (13) 148 (19)
N07 Other nervous system drugs 13 (2) 3 (0)
A Alimentary tract and metabolism 311 (52) 469 (60)
A01 Stomatological preparations 4 (1) 2 (0)
A02 Drugs for acid related disorders 61 (10) 93 (12)
A03 Drugs for functional gastrointestinal
        disorders
57 (9) 24 (3)
A06 Laxatives 108 (18) 105 (13)
A07 Antidiarrheals, intestinal
        antiinflammatory/antiinfective agents
9 (1) 22 (3)
A09 Digestives, incl. enzymes 1 (0) –
A10 Drugs used in diabetes 55 (9) 67 (9)
A11 Vitamins 93 (15) 178 (23)
A12 Mineral supplements 68 (11) 237 (30)
A14 Anabolic agents for systemic use 1 (0) –
A16 Other alimentary tract and metabolism
         products
– 2 (0)
B Blood and blood forming organs 310  (52) 491 (63)
B01 Antithrombotic agents 286 (48) 472 (60)
B02 Antihaemorrhagics – 2 (0)
B03 Antianaemic preparations 42 (7) 70 (9)
M Musculo–skeletal system 273 (45) 283 (36)
M01 Antiinflammatory and antirheumatic
         products
216 (36) 190 (24)
M02 Topical products for joint and muscular
         pain
47 (8) 24 (3)
M03 Muscle relaxants 8 (1) 9 (1)
M04 Antigout preparations 22 (4) 35 (4)
M05 Drugs for treating bone diseases 12 (2) 63 (8)
M09 Other drugs for disorders of the
         musculo-skeletal system
24 (4) 19 (2)
G Genito-urinary system and sex
hormones
108 (18) 127 (16)
G01 Gynaecological antiinfectives and
         antiseptics
1 (0) 1 (0)
G03 Sex hormones and modulators of the
         genital system
37 (6) 60 (8)
G04 Urologicals 77 (13) 77 (10)
R Respiratory system 98 (16) 132 (17)
R01 Nasal preparations 15 (2) 5 (1)
R02 Throat preparations 2 (0) 25 (3)
R03 Drugs for obstructive airway diseases 52 (9) 99 (13)
R05 Cough and cold preparations 20 (3) 6 (1)
R06 Antihistamines for systemic use 23 (4) 29 (4)
H Systemic hormonal preparations,
   excl. sex hormones and insulins
72 (12) 111 (14)
H02 Corticosteroids for systemic use 19 (3) 31 (4)
H03 Thyroid therapy 46 (8) 66 (8)
H05 Calcium homeostasis 9 (1) 18 (2)
S Sensory organs 64 (11) 99 (13)
S01 Ophthalmologicals 60 (10) 99 (13)
S02 Otologicals 1 (0) –
S03 Ophthalmologicals and ontological
         preparations
4 (1) –
D Dermatologicals 44 (7) 21 (3)
D01 Antifungals for dermatological use 7 (1) 4 (1)
D02 Emollients and protectives 16 (3) 4 (1)
D03 Preparations for treatment of wounds
         and ulcers
3 (0) 1 (0)
D06 Antibiotics and chemotherapeutics for
         dermatological use
4 (1) 3 (0)
D07 Corticosteroids, dermatological
         preparations
22 (4) 14 (2)
D10 Anti-acne preparations 1 (0) –
D11 Other dermatological preparations 2 (0) –
J Antiinfectives for systemic use 45 (7) 62 (8)
J01 Antibacterials for systemic use 44 (7) 61 (8)
J02 Antimycotics for systemic use 1 (0) 1 (0)
L Antineoplastic and immunomodulating
agents
8 (1) 14 (2)
L01 Antineoplastic agents 3 (0) 1 (0)
L02 Endocrine therapy 5 (1) 7 (1)
L03 Immunosuppressants – 6 (1)
P Antiparasitic products, insecticides and
repellents
4 (1) 5 (1)
P01 Antiprotozoals 4 (1) 5 (1)
Appendix 7. Drug use according to ATC classification in survivors aged 75 years and older
over the periods 1998–2003 (Kuopio 75+ Study) and 2004–2007 (GeMS Study, control
group)
Kuopio 75+ GeMS
ATC code
1998
n=339
2003
n=339
2004
n=294
2007
n=294
C Cardiovascular system 266 (78) 289 (85) 239 (81) 255 (87)
C01 Cardiac therapy 183 (54) 194 (57) 105 (36) 123 (42)
C02 Antihypertensives 3 (1) 1 (0) – 3 (1)
C03 Diuretics 93 (27) 138 (41) 74 (25) 98 (33)
C04 Peripheral vasodilators 7 (2) 5 (1) 2 (1) –
C05 Vasoprotectives 6 (2) 1 (0) – 1 (0)
C07 Beta blocking agents 158 (47) 174 (51) 148 (50) 165 (56)
C08 Calcium channel blockers 61 (18) 69 (20) 72 (24) 83 (28)
C09 Agents acting on the
         renin-angiotensin system
66 (19) 101 (30) 94 (32) 104 (35)
C10 Lipid modifying agents 25 (7) 41 (12) 87 (30) 108 (37)
N Nervous system 227 (67) 236 (70) 176 (60) 197 (67)
N02 Analgesics 153 (45) 139 (41) 100 (34) 147 (50)
N03 Antiepileptics 2 (1) 4 (1) 5 (2) 8 (3)
N04 Anti-Parkinson drugs 3 (1) 4 (1) 3 (1) 3 (1)
N05 Psycholeptics 112 (33) 168 (50) 97 (33) 106 (36)
N06 Psychoanaleptics 28 (8) 67 (20) 53 (18) 80 (27)
N07 Other nervous system drugs 6 (2) 2 (1) 3 (1) 2 (1)
A Alimentary tract and metabolism 148 (44) 214 (63) 171 (58) 183 (62)
A01 Stomatological preparations 2 (1) 1 (0) – 1 (0)
A02 Drugs for acid related disorders 28 (8) 33 (10) 28 (9) 36 (12)
A03 Drugs for functional
        gastrointestinal disorders
29 (9) 23 (7) 4 (1) 5 (2)
A04 Antiemetics and antinauseants – – – 1 (0)
A06 Laxatives 25 (7) 65 (19) 27 (9) 48 (16)
A07 Antidiarrheals, intestinal
        antiinflammatory/antiinfective agents
3 (1) 7 (2) 12 (4) 9 (3)
A09 Digestives, incl. enzymes – 1 (0) – –
A10 Drugs used in diabetes 26 (8) 32 (9) 21 (7) 31 (10)
A11 Vitamins 60 (18) 89 (26) 73 (25) 53 (18)
A12 Mineral supplements 37 (11) 86 (25) 89 (30) 99 (34)
A16 Other alimentary tract and metabolism
         products
– – 1 (0) –
B Blood and blood forming organs 169 (50) 232 (68) 175 (59) 204 (69)
B01 Antithrombotic agents 160 (47) 222 (65) 171 (58) 192 (65)
B02 Antihaemorrhagics – – – 1 (0)
B03 Antianaemic preparations 14 (4) 40 (12) 22 (7) 32 (11)
M Musculo-skeletal system 159 (47) 140 (41) 101 (34) 84 (29)
M01 Antiinflammatory and antirheumatic
         products
126 (37) 102 (30) 71 (24) 40 (14)
M02 Topical products for joint and
         muscular pain
34 (10) 16 (5) 4 (1) 9 (3)
M03 Muscle relaxants 6 (2) 6 (2) 3 (1) 1 (0)
M04 Antigout preparations 10 (3) 17 (5) 11 (4) 11 (4)
M05 Drugs for treating bone diseases 4 (1) 18 (5) 27 (9) 29 (10)
M09 Other drugs for disorders of the
         musculo-skeletal system
16 (5) 10 (3) 7 (2) 2 (1)
G Genito-urinary system and
    sex hormones
59 (17) 47 (14) 49 (17) 58 (20)
G01 Gynaecological antiinfectives and
         antiseptics
1 (0) – 1 (0) –
G03 Sex hormones and modulators of the
         genital system
30 (9) 17 (5) 24 (8) 28 (9)
G04 Urologicals 34 (10) 31 (9) 29 (10) 32 (11)
R Respiratory system 49 (14) 46 (14) 49 (17) 47 (16)
R01 Nasal preparations 12 (3) 7 (2) 9 (3) 2 (1)
R03 Drugs for obstructive airway diseases 22 (16) 30 (9) 34 (12) 40 (14)
R05 Cough and cold preparations 12 (5) 4 (1) 2 (1) 3 (1)
R06 Antihistamines for systemic use 14 (4) 13 (4) 15 (5) 13 (4)
H Systemic hormonal preparations,
    excl. sex hormones and insulins
43 (13) 60 (18) 41 (14) 45 (15)
H02 Corticosteroids for systemic use 8 (2) 14 (4) 14 (5) 12 (4)
H03 Thyroid therapy 32 (9) 36 (11) 22 (7) 28 (9)
H05 Calcium homeostasis 3 (1) 14 (4) 7 (2) 7 (2)
S Sensory organs 34 (10) 47 (14) 38 (13) 39 (13)
S01 Ophthalmologicals 31 (9) 47 (14) 38 (13) 39 (13)
S03 Ophthalmologicals and otological
         preparations
3 (1) – – –
D Dermatologicals 28 (8) 9 (3) 9 (3) 9 (3)
D01 Antifungals for dermatological use 2 (1) 1 (0) – 1 (0)
D02 Emollients and protectives 10 (3) 4 (1) 2 (1) 1 (0)
D03 Preparations for treatment of wounds
         and ulcers
2 (1) 1 (0) 1 (0) –
D06 Antibiotics and chemotherapeutics for
         dermatological use
3 (1) 2 (1) 1(0) 1 (0)
D07 Corticosteroids, dermatological
        preparations
13 (4) 5 (1) 5 (2) 7 (2)
D10 Anti-acne preparations 1 (0) – – –
D11 Other dermatological preparations 2 (1) – – –
J Antiinfectives for systemic use 20 (6) 51 (15) 13 (4) 24 (8)
J01 Antibacterials for systemic use 19 (6) 51 (15) 12 (4) 24 (8)
J02 Antimycotics for systemic use 1 (0) – 1 (0) –
L Antineoplastic and
   immunomodulating agents
1 (0) 7 (2) 7 (2) 9 (3)
L01 Antineoplastic agents – 1 (0) 1 (0) 1 (0)
L02 Endocrine therapy 1 (0) 6 (2) 4 (1) 5 (2)
L04 Immunosuppressants – – 2 (1) 3 (1)
P Antiparasitic products, insecticides
   and repellents
4 (1) 2 (1) 2 (1) 3 (1)
P01 Antiprotozoals 4 (1) 2 (1) 2 (1) 3 (1)
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Increasing use of drugs in elderly 
persons has raised concerns about 
undesirable health outcomes 
associated with polypharmacy. This 
study provides a general overview of 
changes occurred in drug use over 
time and with ageing. The role of 
demographics, diseases and other 
health-related determinants as 
factors associated with polypharmacy 
was also evaluated. It was shown 
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among the most vulnerable. The 
findings support the idea of regular 
assessments of medication as an 
integral part of comprehensive care 
for the elderly.
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